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1. INTRODUCTION 
Siddha system is one of the ancient systems of medicine founded by Siddhars 
who lived a spiritual life in the southern region of India. Siddha system is practiced 
since ancient days nearly BC 10,000 to BC 4000 ago. The Siddhars were the 
embodiment of divine knowledge, with which they served the people to cure diseases. 
This practice has been hereditarily natural by their successors for generations.  It is a 
psychosomatic system of medicine that deals with the relationship between the mind 
and body and aims at maintaining the physical, mental and moral health of an 
individual.  
  “MAs; khkiw Nakiw ahnkt;th nwd;dpd; 
  Ma tPl;il Nthu;fs;kh dplu;fNs ay;yhy; 
Va Ntwpiy atUly; tPe;jplh jpaw;wj; 
J}a ed;kUe; Jiuj;jyh yhnkdr; nrhy;tha;”.    
- Njiuau;2  
According to the Siddha system, human body is based on three vital humors 
Vatham, Pitham, Kapham. These humors are formed by Panchabootham. Disease 
occurs due to derangement of these vital humors
3
.  
The Siddha system of medicine is not only used to cure, but also to prevent 
disease and in turn to increase the life span of human beings. Siddha medicine also 
shows how to lead a healthy life, by following basic principles and eating healthy 
diets. In Siddha system of medicine the drug sources are obtained from plant, mineral, 
metal and animals.
 
Exclusive of Siddha system are Kayakarpam, Attanga yogam, 
Muppu, Varmam, Envagai thervu, Manikkadai nool, Sarakkuvaippu, 32 types of 
internal medicine and 32 types of external medicine. The medicinal nature of the food 
is highly emphasized in this system of medicine, which is stated as, 
“Unave Marunthu Marunthe Unavu”. 
The scientist Paracelsus quoted that, “All substances are poisons there is none 
which is not a poison”. The right dose differentiates a poison from a remedy. The total 
discipline of toxicology is a paramount science and influences human life right from 
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inception and even after death, should exhumation be required. Poison is a substance 
with an interest property that lends to destroy life or impair health. 
In Siddha system of medicine, Manduram (Ferroso ferric oxide) is used as a 
medicine in treating various diseases, especially blood related conditions. The Siddha 
literature stated that manduram is highly useful in haematopoietic process.   
Nowadays, Anaemia like blood related disorders are more prevalent among 
ladies and children’s. In severe condition, mortality may occur. As manduram induces 
haemopoietic process, it safeguards many lives of diseased. By keeping all these facts 
in mind, the author had selected “Preclinical safety evaluation of MANDURA 
CHENTHOORAM” for this dissertation. 
The reason for selecting Mandura Chenthooram is that manduram is easily 
available and also used in numerous formulations. Manduram is one among the 11 
ulogams. The metallic preparations are more effective curing diseases than the herbal 
formulations.  
So, the author is very keen in evaluating the Acute and Sub acute toxicity of 
Mandura Chenthooram which is mentioned in Kannusamy Parambarai vaithiyam. 
This toxicity study of me is just a small step in the right direction of 
establishing the safety of siddha drugs. This is dedicated to the glory of the Siddha 
system. 
 
 
 
 
 
 
 
 
                                   Aim and Objectives 
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2. AIM AND OBJECTIVES 
  
AIM    
To Preclinical safety evaluation of Mandura Chenthooram. 
OBJECTIVES  
To analytical evaluation of Mandura Chenthooram.  
To study the toxicity profile of Mandura Chenthooram. 
SECONDARY OBJECTIVES  
 Literature of review  
 Preparation Mandura Chenthooram. 
 To do the following studies on Mandura Chenthooram.  
 Physicochemical analysis  
 Biochemical analysis  
 Spectroscopic analysis 
 Acute Oral Toxicity study as per OECD guideline-42343 
 Repeated dose 28-days Oral Toxicity study as per OECD 
guideline-407
44 
 
 
                     Review  of Literature 
  
 
 
 
SIDDHA  ASPECT 
Preclinical Safety Evaluation of Mandura Chenthooram   Page 4 
 
1. kz;^uk; 
maj;ijf;fhl;bYk; epiwe;j td;ikAilaJ.  
NtWngau;fs;:  
 maf;fpl;lk;,  
 mar;rpl;lk;,  
 mNahkyk;,  
 fpl;lk;,  
 rpl;lk;,  
 rpl;lhd;,  
 Nyhfkz;^ uk;.  
,jd; Rit, tPupak;, nra;if Kjypad maj;ij xj;jpUf;Fk;. 
Rit   –   ngUk;ghd;ik Jtu;g;G,rpWghd;ik Gspg;G,ifg;G 
tPupak;  -   ntg;gk; 
nra;if –  FUjpg;ngUf;fp, 
           grpAz;lhf;fp 
           cly; cukhf;fp(gyfhup), 
                       cly;Njw;wp(tpahjNgjfhup) 
nghJf;Fzk;: 
“rpl;lnkhd;whw; Nrhig fpistPf;f kj;jpRue; 
Jl;ltpl ghfQ; Rthrikaq; - nfl;lnfhLk; 
ghz;bUky; ePuhik ghOk; gpukpaKd; 
jhz;btpL Kz;buj;j jhJ”. 
nghUSiu:  
kz;^ uj;jpdhy; thjNrhig Kjypa tPf;fq;fs;, mj;jpRuk;, nfhba 
tplghfk;, ,iug;G, fgNfhgk;, Njfk; ntspwy;, fhrk;, ePuhikf;fl;b, gpukpak; 
,it ePq;Fk;. ,uj;jk; tpUj;jpahFk;
4,1,7
. 
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Rj;jp Kiwfs;: 
maf;fpl;lj;ij cuypypl;L ,bj;J, t];jpufhak; nra;J xU gPq;fhd; 
ghj;jpuj;jpy; ,l;L, mjd; Nky; ehd;F mq;Fyk; epw;Fk;gbahff; fhukhd rPikj; 
jpuhl;irf; fhbiatpl;L, ,uz;L thuk; Cwitj;J, nts;isg;g+z;il ,bj;Jg; 
gpope;j rhw;iw Kd;Nghy;tpl;L xU thuk; Cwitf;f Ntz;Lk;. Cwitf;Fk; 
NghJ, %d;W ehisf;nfhU Kiw Cwitj;j rhw;iw ,ilapilNa 
Cw;wptpl;L, mr;rhw;iwNa Gjpjha; tpl Ntz;Lk;. ,t;tpjk; KiwNa 
Kd;rhWfshy; nra;j gpd;G, thJik nea;apy; my;yJ gRtpd; nea;apy; 
rpl;lj;ij ed;wha; tWj;Jg; nghbj;Jf; nfhs;tNj fpl;lj;jpd; Rj;jp.  
(NtW) 
fpl;lj;ij fy;Yuypypl;L ,bj;J, thafd;w xU rl;bapypl;L, mjd;Nky; 
ehd;F gq;F vil Gspapiyiag; Nghl;L, vz;klq;F ePu; tpl;L, xU 
rhkk;(3kzp) Ntfitj;J, Mwpagpd; ,iyiaAk; nghbiaAk;, Nru;j;J 
ed;wha;j; Nja;j;Jf; fOtp cyu;j;jp, Kwj;jpypl;Lg; Gilj;J, ,iyia 
ePf;fptpLf. gpwF, fpl;lg;nghbia mk;kpapypl;Lg; nghbj;J, xU rl;bapypl;L, 
vl;Lg; gq;F Nfh%j;jpuj;ij tpl;L, mLg;Ngw;wpr; rpW jPahy; vupj;J, %j;jpuk; 
Rz;bagpd; ,wf;fp, ePu; tpl;Lf; fOtp vLj;Jf;nfhs;sr; Rj;jpahk;. 
cNyhf kz;^ur; nre;J}uk; 
                 “,Uk;gpdhQ; rpl;il apytizngz; zhz;if 
          ,Uk;gpdhQ; rpl;ilfzp apd;ig- ,Ug;gp 
 miuj;Jg; Glkpl;b ahKNyh fj;ij 
          miuj;Jg;G kz;^ u khk;”;. 
nghUSiu:  
,Uk;gpdhy; tplg;gl;L mf;fpdpapy; nte;J nkOfpd; gjj;jpy; fl;bahd 
rpl;lj;ij, ghjp epiwahd gQ;rytzKk;, fe;jpAk;, ,urKk;, kpsF, jpg;gpyp, 
Rf;F, cs;sp ,e;j ehd;Fk;, ,itfis nts;shl;L ePupy; Cwitj;J miuj;J, 
ek;khNy nra;ag;gl;l, ed;ikahd gzpf;if, ifahe;jfiur; rhw;wpYk;, Jsrpr; 
rhw;wpYk; fye;J, kj;jpj;J kUe;ij tpy;iy jl;b mt;thNw mbf;fb 
Glj;ijAk; Nghl;nlLg;ghahf ehd;F ehl;fSf;nfhUKiw ,g;gbahfNt ,e;j 
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cNyhfj;ijr; nra;jhy;, miuthrp rpte;j epwKs;s kz;^ ur; nre;J}ukhFk;. 
,jid,  
“Mjp Nyhfj; jankDQ;rpl;lj;jpw; 
 ghjp Nyhfg; ghlyp Njhd;wNt 
     Ntjp ahJ tptukij ehnlhWk; 
        Xjp Nahjp nahopanthz; zhjNuh”. 
vd;Dk; khGuhzr; nra;AshYkwpf. 
msT:  
        xU Fd;wp    – cj;jkk; 
        ,uz;L Fd;wp – kj;jpkk; 
    %d;W Fd;wp – mjkk; 
    ehd;F Fd;wp – mjkhjkk; 
,r;nre;J}uj;ijg; Grpf;f Vw;w epyk;, khjk;, ehl;gpukhzk; Kjypad 
mar;nre;J}uj;jpw;Ff; $wpait Nghd;wdNtahFk;. 
epyk;:  
     thjk;  
      Ky;iy – cj;jkk; 
      FwpQ;rp – kj;jpkk; 
      nea;jy; - mjkk; 
     gpj;jk; 
      nea;jy; - cj;jkk; 
   FwpQ;rp – kj;jpkk; 
   Ky;iy - mjkk; 
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fgk; 
      Ky;iy – cj;jkk; 
      nea;jy; - kj;jpkk; 
      FwpQ;rp - mjkk; 
thjk; Kjy; %tif Nehapdu;fSf;F kUjk; cj;jkj;jpy; cj;jkk;, ghiy 
mjkj;jpy; mjkk; MFk;. 
nre;J}uk;(NtW) 
ehl;nrd;w ehd;F gyk;(140 fpuhk;) kz;^uj;ij ,bj;J ehd;Fgb(5.2 
kp.yp) nts;shl;L ePupy; xU ehs; Cwitj;J ePu;r;Rz;lf;fha;r;rp, gpwF 
neUg;gpypl;L gOf;ff;fha;r;rp, gRePupy; gj;JKiw Njha;j;Jf; fOtp vLj;J, 
fy;tj;jpypl;Lr; Nrhw;Wf; fw;whior; rhw;why; xU ehsiuj;J, tpy;iy jl;b, 
cyu;e;j gpd; Xl;bypl;Lr; rPiy kz; nra;J, ,uz;L Ko cauk; Glk; NghlTk;, 
,t;tpjkhfr; Nrhw;Wf; fw;whior; rhw;wpy; gj;Jg; GlKk;, ePu;Ks;sp, 
fupryhq;fz;zp, tPop, Ntypg;gUj;jp, khJsk; gok; ,itfspd; rhw;wpdhy; 
tiff;Fg; gj;Jg; GlKk; Nghl;L vLj;J itj;Jf;nfhz;L, ,jpy; Ntisf;Fg; 
gzntil(488 kp.fpuh) tPjk;, fupryhq;fz;zpr; rhw;wpy;, jpdk; fhiy khiy 
,UNtisAk; nfhLf;f kNfhjuk;, tp~ghfk;, tplePu;f;Nfhit, ghz;L, Nrhif, 
#iy, Fd;kk;, ePu;f;fLg;G, jhfk;, thjk;, Fly;thjk;, fpufzp Kjypad jPUk;. 
Rj;j kz;^ uk;, kfh kz;^ uk;, rpj;j kz;^ uk;, jpupfLfhjp kz;^ uk;, 
ehuhaz kz;^ uk; vd kz;^ uk; Nru;j;Jr; nra;ag;gLk; kUe;J Kiwfs; gy 
cs;sd. 
,itfspd; nghJf;Fzk;, 
“Rj;jkz; ^ue; Jjpkfh kz;^uQ; 
         rpj;jkz; ^ue; jpupfLf – nkhj;jpLkz; 
        ^ueh uazkz; ^ukpit fl;FntF 
               J}ukhk; ghz;nlhLNrh ig”. 
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nghUSiu:  
Rj;j kz;^ uk;, kfh kz;^ uk;, rpj;j kz;^ uk;, jpupfLfhjp kz;^ uk;, 
ehuhaz kz;^ uk; ,itfspdhy; Itifg; ghz;L Neha;fSk; MWtpjr; Nrhig 
Neha;fSk; xopAk;. 
kfh kz;^uk; 
jpupfLF, jpupgiy, tha;tplq;fk;, kQ;rs;, rpj;jpu%y Ntu;g;gl;il, 
,itfspd; #uzk; rkntil $l;b, ,jw;Fr; rkntil kz;^ uk; Nru;j;Jf; 
fuprhiyr; rhw;why; miuj;Jf; nfhs;sTk;. 
msT: ,ye;ijf; nfhl;il. 
Jiz kUe;J: ru;f;fiu, nea;. 
jPUk; Neha;: ghz;L, Nrhig. 
rpj;j kz;^uk; 
Nfh %j;jpuj;jpy; Rj;jp nra;j kz;^ uk; gyk; vl;ilg;(280 fpuhk;) 
nghbj;J, Ez;zpa J}shf;fp, mWgj;J ehd;F gyk;(2.240 fp.fpuhk;) Nfh 
ePupypl;L mLg;Ngw;wpf; nfhjpf;f itj;Jf; Fok;G gf;Ftj;jpy; tUk; NghJ, 
jpupgiy, jpg;gpyp%yk;, jpupfLF, nrt;tpak;, rptijNtu;, rhwilNtu;, 
fLFNuhfpzp, tha;tplq;fk;, Njthuk;, kQ;rs;, kukQ;rs;, rpj;jpu%yk;, 
Flrg;ghiy tpj;J, Nfhiuf; fpoq;F, G~;fu%yk;(Nfh~;lk;), ehgp, thsk; 
,itfspd; #uzk; tiff;Fg; gyk; xd;W Nru;j;J, Nkw;gb Fok;gpy; $l;bg; 
gpire;J nfhs;sTk;. 
msT: fow;rpasT 
Jiz kUe;J: Nkhu; 
jPUk; Neha;: ghz;L, Nrhig.  
jpupfLfhjp kz;^uk; 
jpupfLF, jpupgiy, Vyk;, rhjpf;fha;, fpuhk;G, fhl;lhj;jpg;g+, jpg;gpyp%yk;, 
Nfhiuf;fpoq;F, rlhkhQ;rpy;, fu;f;flfrpq;fp ,itfisr; #uzk; nra;J, 
rkghfq;$l;b $l;ba vilf;Fr; rupahf kz;^ ug; nghb $l;b, kz;^ u vilf;Fg; 
Preclinical Safety Evaluation of Mandura Chenthooram   Page 9 
 
ghjp Nyhfg;nghb $l;b fuprhiyr; rhw;whyiuj;J, ,ye;ijf; nfhl;il msT 
khj;jpiu nra;J nfhs;sTk;.  
mDghdk;: ru;f;fiu, Njd;. 
jPUk; Neha;fs;: ghz;L, Nrhig, fhkhiy, rak;, Ruk;. grp cz;lhk;. 
ehuhaz kz;^uk; 
jpupfLF, jpupgiy, jpg;gpyp%yk;, ahidj;jpg;gpyp, nrt;tpak;, rpWNjf;F, 
Xkk;, FNuhrhzp Xkk;, trk;G, kQ;rs;, fLFNuhfpzp, nts;Ss;sp, ngUq;fhak;, 
kapypwFr;rhk;gy;, thsk;, gpuz;il, fhl;lhj;jpg;g+, epyNtk;G, rhjpf;fha;, 
jz;zPu;tpl;lhd;, Kl;fhNtisNtu;, rhwilNtu;, fuprhiy, MytpOJ, 
Jk;kl;bf;fha; ,itfisr; rkghfnkLj;Jr; Nru;j;J, Nru;e;j vilf;Fr; rkd; 
kz;^ uq; $l;b, MlhNjhilr;rhW, fuprhiyr;rhW, vYkpr;rk; gor;rhW, 
,Q;rpr;rhW, Mapy;gl;ilf; FbePu;, njspe;j fhb, ney;ypf;fha;r; rhW 
,itfspy; KiwNa miuj;Jf; nfhs;f. 
msT: Gspaq;nfhl;il, fhiy, khiy 
Jiz kUe;J: nte;ePu;, Nkhu;. 
jPUk; Neha;fs;: ghz;L, Nrhig, fhkhiy, mf;fpdpke;jk;, Fd;kk;, #iy, ghupr 
#iy, gPeprk;, Rthrfhrk;, mUrp Kjypait. 
kz;^ur;nre;J}uk; 
ruf;Fk; nra;ghfKk;: 
Ie;J gyk; ehl;nrd;w kz;^ uj;ijf; nfhz;Lte;J fd;dhd; ciyapy; 
itj;Jg; gOf;f Cjpf; Nfhtpd; ePupy; Njha;f;fTk;. ,g;gb Ie;J Kiwf; 
fha;r;rpf; fha;r;rpf; Njha;f;fr; Rj;jpahFk;. ,ij, <ukpy;yhky; Jilj;Jf; 
fy;Yuypy; Nghl;Lf; flg;ghiwnfhz;L khTNghy; ,bj;Jf; fy;tj;jpy; Nghl;Lf; 
fuprhiyr;rhw;wpy; xU ehSk;, Fkupr;rhw;wpy; xU ehSk; ed;whaiuj;J 
nkOFgjj;jpy; tpy;iy jl;b utpapy; cyu;j;jp mfypy; itj;J Nky; mfy; 
%br; rPiy nra;J 50 twl;bapy; GlkplTk;. ,g;gbNa fuprhiyr;rhw;wpy; 
miuj;J miuj;J Kd;Nghy; tpy;iy jl;b mfypy; itj;J Nky; mfy; %br; 
rPiy nra;J 10-15 Glk; tiuapy; Nghl;Ltu cau;jukhd nre;J}ukhFk;. 
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msT: xU Fd;wp 
ehssT: ,UNtis, 1/2-1 kz;lyk;. 
jPUk; Neha;fs;: vupFd;kk;, rj;jpFd;kk;, gpj;jFd;kk;, Rug;ghz;L, gpj;jghz;L, 
thjNuhfk;, gpj;jNuhfk;, rpNyj;JkNuhfk;, fhkhiy, ghz;L. jhJG~;b 
cz;lhFk;1. 
fUq;Fok;G 
                    “fl;lhf tpd;dq; foWfpNwd; ty;yj;Jf; 
         fpl;lnkhL fhe;jq; fpUigaha; - el;lkpy;iy 
         ePu;tbapd; Kj;J epiwaha;f; foQ;nrhd;W 
         Neu;thsk; ,uz;lhF Neu;”. 
           “Neu;e;jpj;j ehw;ruf;if NeupioNa Rj;jpnra;J 
         Nghu;epiwe;j fy;tj;jpw; Nghl;liug;gha; - rPuhf 
         Nkjpr; rpkps;itj;J Ntz;bg; gzntiljhd; 
         ghjpgid nty;yj;jpw; gha;r;R” 
                    “nty;ykjp Yz;Lghu; nky;ypau;fs; #jfKk; 
         my;Y}Uq; fl;beP uhk;gnyq;Nf – nrhy;yf;Nfs; 
         fhZ kNfhjuKq; fhkhiy fha;r;rw;fl;b 
         g+Zgy thATk; Nghk;”. 
nghUSiu:  
ty;yj;Jr; rpl;lk;, fhe;jk;, Njhy; ePf;fpa ePubKj;J ,it tiff;F xU 
foQ;Rk;(5.1fpuhk;) Neu;thsk; ,U foQ;Rk;(10.2fpuhk;) Rj;jp nra;J, 
fy;tj;jpypl;L nkOF gjkhf miuj;J, vUikf; nfhk;Gr; rpkpopy; 
itj;Jf;nfhs;sTk;. 
msT: miug; gzntil(244kp.fpuhk;) 
Jiz kUe;J: gidnty;yj;jpw;Fs; itj;J mUe;Jf. 
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jPUk; Neha;fs;: #jf tha;T, ,uj;j thj Fd;kf;fl;b, ePuhk;gy;, kNfhjuk;, 
fhkhiy, fha;r;rw;fl;b, thjNeha;fs;. 
kz;^u khj;jpiu 
fpl;lk;, fhe;jk;, ,e;Jg;G, fUQ;rPufk;, jpupfLF, ,it tif xd;Wf;F 
xU gyk; ,tw;iwf; fy;tj;jpypl;Lf; ifahe;jfiur;rhw;why; %d;W ehs; 12 
rhkk; miuj;Jf; fhrsT tpy;iyfs; nra;Jitj;Jf; nfhs;sTk;.  
ehs; msT: VO ehs;, fhiy, khiy. 
Jiz kUe;J: Njd;. 
jPUk; Neha;fs;: gpj;jg;ghz;L, tp~g;ghz;L. 
gj;jpak;: cg;G
4
.  
kz;^uk; NrUk; kUe;Jfs;: 
1. jpup%u;j;jp nre;J}uk;: 
   msT: 1-11/2 Fd;wp (130-195mg) 
   Jiz kUe;J: nea;, Njd;. 
   jPUk; Neha;fs;: ghz;L, Nrhif, fhkhiy
5
. 
2. Rj;j kz;^ ur; nre;J}uk; 
msT: 1-11/2 Fd;wp (130-195mg) 
Jiz kUe;J: nea;, Njd;. 
jPUk; Neha;fs;: ghz;L, Rthrfhrk;
5
. 
3. k`h kz;^ ur;nre;J}uk; 
msT: 1-11/2 Fd;wp.(130-195mg) 
jPUk; Neha;fs;: tPf;fNuhfq;fs;
5
.; 
4. kz;^ u khj;jpiu: 
msT: Fd;wpg; gpukhzk;, fhiy,khiy 
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jPUk; Neha;fs;: kz;zPuy; tPf;fk;, fhkhiy, ghz;L, CU];jk;g thjk;, 
%yNuhfk;, Ruk;5. 
5. ,Uk;G rpl;lfw;gk;: 
msT: 10 – 20 Fd;wp 
jPUk; Neha;: Cjy; Neha;.6  
6. kz;^ ur; nre;J}uk;: 
msT: 1 Fd;wp 
mDghdk;: fupryhq;fz;zpr;rhW 
jPUk; Neha;: kNfhjuk;, tp~ePu;f;Nfhit, ghz;L, Nrhig, Fd;kk;, 
fpuhzp
7
.  
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2. gRePu; 
NtWngau;: 
 ePu;, 
 mKup, 
 %j;jpuk;, 
“....................................... ePu; rpW ePuKup 
%j;jpunkd; NwngaNuhu; %d;W” vd;w mbfshy; czu;f. 
gR %j;jpuf; Fzk;: 
“tplghz;L Nrhiggy tPf;fQ; rfy 
tplKjpu khiynad nkj;jg; - Gltpjdpw; 
Ngryf;f NzhLje;jg; gPil afd;wpLNk 
Nfhryj;jh yhuzq;Nf $W.” 
nghUSiu:  
Nfhryj;jhy; tp~g;ghz;L, Nrhig, gw;gy tPf;fk;, rfy tp~k;, mrpu;f;F, 
fhkhiy, gy;Neha; Kjypa gpzpfs; Nghk;. 
nra;if: 
rpWePu;g; ngUf;fp 
kykpsf;fp.  
gRtpd; ePu; cs;Sf;Fk; ntspf;Fk; gad;gLj;jg;gLfpwJ. 
gRePupd; cgNahfk;: 
 gRtpd; ePiu tbfl;b, xd;W Kjy; ,uz;L mTd;]; tiu nfhLj;Jtu, 
mFit, kNfhjuk;, ePu;f;fl;L, kyf;fl;L, ngUNeha;, Njhy; rk;ge;jg;gl;l 
gpzpfs; jPUk;. 
 vl;L mTd;]; gRtpd; ePupy;, xU fLf;fha;j; Njhypl;L Cwitj;J 
fye;J tbfl;b, Xu; mTd;]; ePiuf; nfhLf;f, mFit, kNfhjuj;jpy; 
cz;lhk; kyryf;fl;L ,tw;iw ePf;fpf; Fzk; jUk;. 
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 ,Utp, ehgp ,it Nghd;witfisj; jdpj;jdpg; gRtpd; %j;jpuj;jpy; 
%d;W ehs; Cwitj;njLf;fr; Rj;jpahk;. 
 mak;, cUf;F, kz;^ uk; ,itfisj; jdpj;jdpahff; nfhy;yd; 
ciyapypl;Lf; fha;r;rp gd;Kiw gRtpd; ePupy; Njha;j;njLf;fr; 
Rj;jpahFk;
8
.  
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3. ntw;wpiy 
NtW ngau;:- 
 jhk;g+yk;, 
 jhk;g+yty;yp, 
 jpiuay;, 
 ehfty;yp, 
 nky;ypiy, 
 nts;spiy, 
 nky;ylF 
 
 ,J ,e;jpahtpy; ntg;g ghfj;jpYk;, rJg;Gs;s ,lq;fspYk; gapu; 
nra;ag;gLk; kuNkWq; nfhb. ,J ,iyapd; nghUl;Nl gapuplg;gLfpwJ. 
 ,J ,iyapd; epwj;jhYk;, kzj;jhYk;, fhu;g;Gr; RitahYk; 
%tifg;gLk;. kpFe;j kzKk;, fhuKk;, fUg;G epwKk; ,y;yhjJ 
“ntw;wpiy”, fUikAk; fhuKk; kpFe;jJ “fk;khW ntw;wpiy”, fUg;g+u 
kzKk;, rpWfhuKKilaJ “fUg;g+u ntw;wpiy”.  
gad;gLk; cWg;G: ,iy 
Rit – tpWtpWg;G,fhu;g;G 
jd;ik – ntg;gk;, 
gpupT – fhu;g;G 
nra;if: 
ntg;gKz;lhf;fp 
mfl;Ltha;tfw;wp 
Jtu;g;gp 
fhkk;ngUf;fp 
mOfyfw;wp 
ntg;gfw;wp 
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grpj;jPj;J}z;b 
ghw;ngUf;fp 
ckpo;ePu;g;ngUf;fp 
nghJFzk;: 
“vl;bnyhd;W fpl;bdP Nuw;wQ; rpNuhghu 
khl;b tpLrd;dp khe;jnkhL – ehl;bw; 
gupaFuw; fk;kty;yp gz;bAg;gp rk;Ngh 
kupafk; khWntw;wp iy.       (m.F) 
fk;khW ntw;wpiyahy; ePNuw;wk;, jiyghuk;, Kg;gpzp, khe;jk;, Fuw;fk;ky;, 
tapw;Wtyp, tapw;Wg;gprk; Nghk;
9
. 
NrUk; kUe;Jfs;;  
1. ,urf;fw;g+u nkOF:  
msT: 4 - 7 Fd;wp vil  
mDghdk;: gid nty;yk;   
jPUk; Neha;: #iy Neha;> Gz;fs;, ntl;il
10
.  
2. tp~j;jpw;F m[%j;uhjp kUe;J:  
msT: 1 Fd;wp vil  
mDghdk;: ntw;wpiy   
jPUk; Neha;: tp~q;fs;
11
;.  
3. fpue;jp cUz;il: 
msT: 2-3 khj;jpiu 
Jiz kUe;J: nty;yk;, gidnty;yk;, thiog;gok; 
jPUk; Neha;: fpue;jp, miuahg;G, fz;lkhiy, mupfpue;jp, gpsit, 
Nkfk
;12
;. 
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4. Ntg;gpiy fUf;Ff;fpahok; 
msT: tPrk;gb, ,UNtis 
jPUk; Neha;: the;jp, Xf;fhsk;13. 
.5. matPur;nre;J}uk; 
msT:1/4-1/2 Fd;wp, ,UNtis 
mDghdk;: Njd;, gdntl;L 
jPUk; Neha;: ghuprthjk;, Kfthjk;, [d;d;p, Ruk;, Filr;ry;, 
NkfthAtpdhy; cz;lhd gpbg;G13. 
6. gQ;r gh~hz nre;J}uk; 
msT: muprpnail, ,UNtis 5-7 ehl;fs; 
jPUk; Neha;:#iy, [d;dp, Nkfk;, ntz;Fl;lk;, Ruk;, thjk;80, fuhzp, 
Fd;kk;, gpsit, fz;lkhiy, mz;lthjk;, gTj;jpuk;,  Rthrfhrk;, fpue;jp, 
Gj;J, Fl;lk;, mupfug;ghd;, nrhupfug;ghd;, f[ru;kNuhfk;, GOntl;L13. 
tof;F:  
 njhz;ilailg;G> Fuy;fk;kypy; ntw;wpiyiaAk; rhk;gpuhzpg; 
gjq;fj;ijAk; nkd;W Ritf;Fk;gb nra;ayhk;.  
 ghw;Ruf;fTk;> ghy; fl;b cz;lhFk; Kiy tPf;fj;ijf; fiuf;fTk; 
ntw;wpiyiaj; jzypy; thl;b mLf;fLf;fhf itj;Jf;fl;lTk;.  
 ntw;wpiyia vz;nzapy; eidj;J> tpsff;fpy;thl;b khHgpd; Nky; 
Nghl ,Uky;> %r;RKl;ly;> fbdRthrk;> Foe;ijfSf;Fz;lhFk;; ,Uky; 
tpyFk;. ,itfl;Nf ntw;wpiyr; rhw;Wld;; Rz;zhk;Gf;; $l;b 
njhz;ilf;; Fopapy; jltyhk;.   
 ntw;wpiyr; rhw;Wld;; ,Q;rpr;rhWk; NrHj;J> EiuaPuy; rk;ge;jkhd 
Nehapy; toq;fyhk;.  
 jiyg;gSTf;F %f;fpYk;, fhJ Fj;jYf;F mf;fhjpYk; ntw;wpiyr; 
rhw;wpy; 2 – 3 Jsp tplyhk;.  
 jPg;gl;l Gz;zpd;kPJ ntw;wpiyia itj;Jf;; fl;lyhk;.  
 ghjurk;> ntw;wpiyr; rhw;why; Jha;ikahk;.  
 2-3 ntw;wpiyAld; 4-5 kpsF NrHj;Jf; FbePhpl;Lg; Gfl;l 
rpWtHfSf;Fz;lhFk; nrhpahik tpyFk;.  
 ntw;wpiyr; rhw;wpy; nfhQ;rk; NfhNuhrdQ; NrHj;Jg; Gfl;l 
Nfhiof;fl;L, ,Uky; %r;Rj; jpzwy; FzkhFk;.  
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 rpWgps;isfSf;Fz;lhFk; tapw;Wg; nghUky;> kyf;fl;L; ,itfisg; 
Nghf;f> ntw;wpiyf; fhk;ig Mkzf;F nea;apy; eidj;J> fPo;thapy; 
itf;fyhk;.  
 fhkg;ngUf;if cz;lhf;Fk; nghUl;fSld; NrHj;Jz;z fytpapy; 
,r;ir cz;lhFk;
9
. 
 ma gw;gk;, nrk;G gw;gk;, jq;f gw;gk; kUe;JfSf;F mDghdkhf 
gad;gLfpwJ. 
 g+uj;jpid Rj;jp nra;a fk;khW ntw;wpiy cjTfpwJ4. 
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4. nehr;rp 
NtW ngau;:  
 ,e;jpu#upak;, 
 epj;jpy;, 
 epu;f;Fz;b, 
 neu;f;Fz;b, 
 rpe;Jk rpe;Jthuk;. 
 ,J ,e;jpah KOtJk; tsUfpd;w xU rpwpakuk;. 
 ,jpy; fUnehr;rp, ePu;nehr;rp, ntz;nzhr;rp vdg; gpupTfs; cs;sJ. 
ntz;nzhr;rp vq;Fk; fpilf;ff;$baJ. fUnehr;rp fpilg;gJ mupJ. 
ePu;nehr;rp jhkputUzp Mw;wq;fiuapYz;L. 
gad;gLk; cWg;G: ,iy,g+,Ntu;,gl;il 
Rit – ifg;G, Jtu;g;G,fhu;g;G 
jd;ik – ntg;gk; 
gpupT – fhu;g;G 
nra;if: 
nghJ 
cly;Njw;wp 
GOtfw;wp 
Ntu; 
ntg;gfw;wp 
Nfhioafw;wp 
rpWePu;g;ngUf;fp 
g+ 
Jtu;g;gp
9
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nehr;rp NrUk; kUe;Jfs;: 
1. rd;dpthjRuf; FbePu:; 
msT: 30-60 kp.yp.
14. 
2. epu;Fz;bj;ijyk:; 
msT: Jl;bilasT 
jPUk; Neha;fs;: 5tif fhrNuhfq;fs;;;;;;, ~aNuhfq;fs;
15
. 
3. Foe;ijfs; khe;j fpahok;:  
msT: 1 rq;F msT,3-4 Ntis 
jPUk; Neha;: khe;jk; ePq;Fk;
16. 
4. Nrhjpuprpj;ijyk;: 
msT: 1 fhR vil 
jPUk; Neha;: rfy typg;GfSk; ePq;Fk;
17
. 
5. nrq;fj;jhup vz;nza;:  
msT: 1 Njf;fuz;b 
jPUk;Neha;: 
 Gil, 
 nfhs;sp, 
 tPq;F, 
 gpj;jthjk;, 
 nrq;fug;ghd;, 
 mupfug;ghd;, 
 fUq;fug;ghd;
17
.  
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5. nts;shl;Lg;ghy; 
NtWngau;: 
 gak;, 
 fPuk;, 
 Rij, 
 gaR, 
 ghF, 
 mKJ, 
 Jj;jk;, 
 rhW. 
,jw;F xg;ghd xUtpjg;ghYk; ,y;iy
19. 
nts;shl;Lg;ghy; Fzk;: 
“nts;shl;L ghYf;FNktpaew; wPgdkhe; 
js;shL thjgpj;jQ; rhe;jkhk; - cs;spiug;Gr; 
rPjkjp rhuQ; rpNy~;kkWk; Gz;zhWk; 
thj rpNy~;kKg;Ngh kha;e;J.” 
nghUSiu:  
nts;shl;Lg; ghypdhy; thjgpj;j njhe;jk;, Rthrfhrk;, rPjhjprhuk;, 
fgNjh~k;, tpuzk;, thjj;jpYz;lhfpa tPf;fk;, Kjypa Jd;ge; jPUk;. ey;y 
grpAk; cz;lhFk;. 
nts;shl;Lg;ghy;:  
 Cd; nra; nghUSk;, nfhOg;Gg; nghUSk; FiwTgl;l nts;shl;Lg;ghy; 
,dpg;gpYk; FiwTgl;bUf;fpwJ. ,J tpiutpy; nrupf;ff;$baJ. 
kUe;Jz;Zk; Nehahspf;F ,g;ghy; rpwe;j gj;jpag; nghUshFk;.  
 ePu; kpf;f #l;bdhy; kQ;rs; epwg;gl;Lf; Fiwe;j nghOJ ,g;ghiy 
cz;Lte;jhy; mJ tpiutpy; FzkhFk;. 
 nts;shl;Lg;ghYld; ePu; Nru;j;Jf; fha;r;rpf; fw;fz;Lj; J}s; Nru;j;J, 
fhiy khiyfspy; mUe;jp tu fgNeha;fs; ePq;Fk;. 
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 ghz;L, Nrhig, fhkhiy Mfpa Neha;fSf;F mak;, mafhe;jk; 
,itfshyhfpa nre;J}uq;fis toq;Fk;nghOJ, fha;r;rpa nts;shl;Lg; 
ghiyr; Nrhw;Wld; $l;bg; gj;jpakhf cz;Ltupd; tpiutpy; Neha;fs; 
ePq;Fk;. 
 fiz, fy;yPuy;, kz;zPuy; Kjypa Neha;fspdhy; tUe;Jk; 
Foe;ijfSf;F nts;shl;Lg;ghiy czthf toq;fptu mit 
FzkilAk;. 
 ,isg;G Nehapdhy; tUe;Jfpd;wtu;fs;, gytifj; jhtuq;fis 
cz;Zk; ,ay;Gila nts;shl;Lg; ghiy cz;Ltu gaidj; jUk;. 
 fu;g;gk; jupj;jtu;fSf;Fk;, <uy; gQ;ir gl;ltu;fSf;Fk;, fhf;if 
typf;Fk; gad;glhJ19. 
nts;shl;Lg;ghy; NrUk; kUe;Jfs;: 
 kpsFj;ijyk;,  
 thjNfrupj;ijyk;,  
 mkpu;jhkyfj;ijyk;,  
 epu;f;Fz;bj; ijyk;,  
 %yNahf epu;f;Fz;bj; ijyk;,  
 cSe;Jj; ijyk;,  
 yFtplKl;bj;ijyk;
18
. 
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6. nts;shl;L ePu; 
nts;shl;L %j;jpuf; Fzk;: 
“NrhignahL ghz;Litj;J uj;Jk; gytPf;f 
J}gkfw; Wk;Kjpuj; ijg;Nghf;Fk; - NfhgKld; 
cs;shl;Lj; Ju;r;rijNah Nlhq;Fju Nehafw;Wk; 
nts;shl;L %j;jpuk;tp iue;J.” 
nghUSiu:  
    nts;shl;L %j;jpuk; Nrhig, ghz;L, gw;gy tPf;fj;jpndupr;ry;, 
,uj;jg;Nghf;F, Ju;khkprk;, kNfhjuk; ,itfis ePf;Fk;. 
nra;if: 
rpWePu;g; ngUf;fp 
kykpsf;fp 
nts;shl;L ePupd; cgNahfk;: 
 nts;shl;L %j;jpuj;ij ntJg;gp tbfl;b Ntisf;F xd;W Kjy; 
xd;wiu mTd;]; tPjk; rlhkhQ;rpy; my;yJ jr%yf; FbePUld; 
nfhLf;ff; fhf;iftyp Fzkhk;
20
. 
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7. fw;whio  
NtW ngau;;:  
 fd;dp, 
 Fkup. 
 ,J ,e;jpah Kw;wpYk; Mw;wq;fiufspYk;> rJg;G epyq;fspYk;, 
Njhl;lq;fspYk; gapuhFk;. 
 ,J rpWfw;whio, ngUq;fw;whio, Nga;f;fw;whio, fUq;fw;whio, 
nrq;fw;whio vdg; gytifg;gbDk;, ,jd; nra;if Kjypad 
rw;Nwwf;Fiwa Xj;NjapUf;Fk;. 
gad;gLk; cWg;G: ghy;,klw;NrhW,rhW,Ntu;. 
Rit – rpWifg;G, 
jd;ik – jl;gk; 
gpupT - ,dpg;G 
nra;if: 
cukhf;fp 
clw;Nww;wp 
ePu;kyk;Nghf;fp 
UJcz;lhf;fp 
nghJFzk;: 
“nghy;yhNk fq;fgk;G Or;#iy Fl;lurk; 
my;yhu;kj; jk;gfe;j uq;Fd;kk; vy;yhk;tpl; 
NlF kupf;F nkupr;rw; fpupr;ruK 
khF kupf;F kUz;L”. (Nj.F) 
fw;whioapdhy; thjNkfk;, fUNkfk;, fpUkpf;Fj;jy;, ngU tpahjp, 
%yk;, cd;khjk;, gfe;juk;, Fd;kk;, gpj;jf;fpupr;ruk; Nghk;
9
. 
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fw;whio NrUk; kUe;Jfs;: 
1. Fkup Nyfpak;: 
msT: ½ Njhyh, ,UNtis. 
jPUk; Neha;fs;: Nkf rk;ge;jkhd c~;zk;, fdr;#L, ngz;fSf;F 
cgNahfg;gLj;j fUg;ghrak; gyg;gl;L khjtplhapYz;lhd gyg;gy gpzpfs; 
ePq;fpr; re;jhdghf;fpak; cz;lhFk;
5
. 
2. Kiyg;ghnyz;nza;: 
msT: ngupNahu; - fhyzh vil, xUNtis. 
       Foe;ijfs; - ½ Kjy; 1 fhnril. 
jPUk; Neha;fs;: 
ngupNahu; - vYk;GUf;fp, fpuhzp, mjprhuk;, rPjf;fLg;G, fzr;#L, 
%yr;#L, ehl;gl;l nts;is. 
Foe;ijfs; - c~;z Nuhfq;fs; eptu;j;jpahfpj; NjfG~;b 
cz;lhFk;
5
. 
3. fu;g;g tpUj;jp vz;nza;: 
msT: 2-3 Njhyh, fhiy. 
jPUk; Neha;fs;: ky[yge;jk;, iffhyrjp, thA cgj;jputk;, 
Nkfj;jpdhy; rpR rpijjy; Kjypa Fw;wq;fs; ePq;fpg; g+u;zre;jpud; Nghd;w 
ey;y moFila Foe;ij gpzpnahd;Wkpd;wpg; gpwf;Fk;
5
. 
 
 
  
 
MODERN ASPECT 
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1. MANDURAM 
 (Ferroso ferric oxide – Iron oxide) 
Ferroso ferric oxide is also known as iron rust, impure of iron or ‘Loga 
Manduram’. It is more potent than iron. This substance is obtained by melting the iron 
in a furnace and collecting it in waxy consistency. Its taste, potency and action are 
similar to that of iron21. 
IUPAC name 
Iron (II) iron (III) oxide 
Other names: 
 Eng:Ferrous ferric oxide, Ferroso ferric oxide, Iron (II, III) oxide, Magnetite, 
Black iron oxide, Lodestone, Rust, Iron (II) diiron (III) oxide 
 Sanskrit: Manduram 
 Arab: Khabsul Hadid 
 Pers: Zang-e-ahana 
 Bom: Lohaka janga 
 Hindi: Lohaka-Zang 
 Ben: Lohar-gu 
 Duk: Lohaka-gu; Mandur 
 Guj: Lodhano-kata 
 Tel: Innupa chittumu 
 Mal: Irambak kitane 
 Can: Kabbinada Kilubu or kitta 
 Sinh: Yakada kittam 
 Kon: Lokhanda-gu 
 Burm: Sanpia; Tambia22  
Properties: 
 Chemical formula-Fe3O4, FeO.Fe2O3 
 Appearance-solid black powder 
 Solubility-Insoluble in water and organic solvents; soluble in concentrated 
mineral acids  
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Except where otherwise noted, data are given for materials in their standard 
state (at 25 °C [77 °F], 100 kPa). 
Iron (II, III) oxide is the chemical compound with formula Fe3O4. It occurs in 
nature as the mineral magnetite. It is one of a number of iron oxides, the others being 
iron(II) oxide (FeO), which is rare, and iron(III) oxide (Fe2O3) also known as 
hematite. It contains both Fe2+ and Fe3+ ions and is sometimes formulated as FeO ∙ 
Fe2O3. This iron oxide is encountered in the laboratory as a black powder. It exhibits 
permanent magnetism and is ferrimagnetic, but is sometimes incorrectly described as 
ferromagnetic.Its most extensive use is as a black pigment which is synthesised rather 
than being extracted from the naturally occurring mineral as the particle size and 
shape can be varied by the method of production. 
Preparation: 
Under anaerobic conditions, ferrous hydroxide (Fe (OH) 2) can be oxidized by 
water to form magnetite and molecular hydrogen. This process is described by the 
Schikorr reaction: 
3Fe (OH)2                  Fe3O4 +       H2 +       2H2O 
             Ferrous hydroxide                           Magnetite   Hydrogen   Water 
The well-crystallized magnetite (Fe3O4) is thermodynamically more stable 
than the ferrous hydroxide (Fe (OH) 2). 
Magnetite can be prepared in the laboratory as a ferrofluid in the Massart 
method by mixing iron (II) chloride and iron (III) chloride in the presence of sodium 
hydroxide. Magnetite can also be prepared  
By the chemical co-precipitation in presence of ammonia, which consist in a 
mixture of a solution 0.1 M of FeCl3·6H2O and FeCl2·4H2O with mechanic agitation 
of about 2000 rpm. The molar ratio of FeCl3:FeCl2 can be 2:1; heating this solution at 
70 °C, and immediately the speed is elevated to 7500 rpm and adding quickly a 
solution of NH4OH (10 volume %), immediately a dark precipitate will be formed, 
which consists of nanoparticles of magnetite. In both cases, the precipitation reaction 
rely on a quick transformation of acidic hydrolyzed iron ions into the spinel iron oxide 
structure, by hydrolysis at elevated pH values (above ca. 10). 
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Considerable efforts has been devoted towards controlling the particle 
formation process of magnetite nanoparticles due to the challenging and complex 
chemistry reactions involved in the phase transformations prior to the formation of the 
magnetite spinel structure. Magnetite particles are of interests in bioscience 
applications such as in magnetic resonance imaging (MRI) since iron oxide magnetite 
nanoparticles represent a non-toxic alternative to currently employed gadolinium-
based contrast agents. However, due to lack of control over the specific 
transformations involved in the formation of the particles, truly superparamagnetic 
particles have not yet been prepared from magnetite, i.e. magnetite nanoparticles that 
completely lose their permanent magnetic characteristic in the absence of an external 
magnetic field (which by definition show a coercivity of 0 A/m). The smallest values 
currently reported for nanosized magnetite particles is Hc = 8.5A m−1, whereas the 
largest reported magnetization value is 87 Am2 kg−1 for synthetic magnetite. 
Pigment quality Fe3O4, so called synthetic magnetite, can be prepared using 
processes that use industrial wastes, scrap iron or solutions containing iron salts (e.g. 
those produced as by-products in industrial processes such as the acid vat treatment 
(pickling) of steel): 
 
 Oxidation of Fe metal in the Laux process where nitrobenzene is treated with 
iron metal using FeCl2 as a catalyst to produce aniline: 
                   C6H5NO2 + 3 Fe + 2 H2O → C6H5NH2 + Fe3O4 
 Oxidation of FeII compounds, e.g. the precipitation of iron (II) salts as 
hydroxides followed by oxidation by aeration where careful control of the pH 
determines the oxide produced. 
Reduction of Fe2O3 with hydrogen: 
3Fe2O3 + H2 → 2Fe3O4 +H2O 
Reduction of Fe2O3 with CO: 
3Fe2O3 + CO → 2Fe3O4 + CO2 
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Production of nano-particles can be performed chemically by taking for 
example mixtures of Fe
II
 and Fe
III
 salts and mixing them with alkali to precipitate 
colloidal Fe3O4. The reaction conditions are critical to the process and determine the 
particle size. 
Reactions: 
Reduction of magnetite ore by CO in a blast furnace is used to produce iron as 
part of steel production process: 
Fe3O4+ 4CO - 3Fe+ 4CO2 
Structure 
Fe3O4 has a cubic inverse spinel group structure which consists of a cubic 
close packed array of oxide ions where all of the Fe
2+
 ions occupy half of the 
octahedral sites and the Fe
3+
 are split evenly across the remaining octahedral sites and 
the tetrahedral sites. 
Both FeO and γ-Fe2O3 have a similar cubic close packed array of oxide ions 
and this accounts for the ready interchangeability between the three compounds on 
oxidation and reduction as these reactions entail a relatively small change to the 
overall structure. Fe3O4 samples can be non-stoichiometric. 
The ferrimagnetism of Fe3O4 arises because the electron spins of the Fe
II
 and 
Fe
III
 ions in the octahedral sites are coupled and the spins of the Fe
III
 ions in the 
tetrahedral sites are coupled but anti-parallel to the former. The net effect is that the 
magnetic contributions of both sets are not balanced and there is a permanent 
magnetism. 
Properties: 
Fe3O4 is ferrimagnetic with a Curie temperature of 858 K. There is a phase 
transition at 120K, the so-called Verwey transition where there is a discontinuity in 
the structure, conductivity and magnetic properties. This effect has been extensively 
investigated and whilst various explanations have been proposed, it does not appear to 
be fully understood. 
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Fe3O4 is an electrical conductor with conductivity significantly higher (X 106) 
than Fe2O3, and this is ascribed to electron exchange between the Fe
II
 and Fe
III
 
centres. 
Uses: 
 Fe3O4 is used as a black pigment and is known as C.I pigment black 11 (C.I. 
No.77499) or Mars Black. 
 Fe3O4 is used as a catalyst in the Haber process and in the water gas shift 
reaction. The latter uses an HTS (high temperature shift catalyst) of iron oxide 
stabilised by chromium oxide. This iron-chrome catalyst is reduced at reactor 
start up to generate Fe3O4 from α-Fe2O3 and Cr2O3 to CrO3. 
 Nano particles of Fe3O4 are used as contrast agents in MRI scanning. 
 Ferumoxytol, also known as Feraheme and Rienso, is an intravenous Fe3O4 
preparation for treatment of anemia resulting from chronic kidney 
disease.Ferumoxytol is manufactured and globally distributed by AMAG 
Pharmaceuticals. 
 Along with sulfur and aluminium, it is an ingredient in a specific type of 
thermite useful for cutting steel. 
The Manduram is useful in the following conditions: 
The various preparations are made from red oxide of iron. They are useful in 
anaemic and dropsy
23
. 
Swelling of the lassitude, Fever associated with bone disorders severe 
anasarca and paleness, wheezing dropsy due to abdomen enlargement, Pallor, Asthma 
and Gonorrhoea. It improves the hemopoisis. 
The Manduram should not be used in chronic diseases associated with loss 
appetite, constipation and when there is fever
21
.  
Mandura is especially useful in anaemia, amenorrhoea, dysmenorrhoea, 
menorrhagia, chlorosis; also diarrhoea, chronic bowel complaints, dyspepsia, 
intestinal worms and nervous diseases; neuralgia of the 5
th
 nerve due to debility, 
kidney diseases, albiminuria22.  
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2. COW URINE 
Our ancient pepoles like identify cow urine as a powerful medicine. They 
called it Panchagavya. The treatment of disease using products obtained from cows 
milk, curd, ghee, urine and dung. Cow urine when used as a form of medicine and 
also helps to medicine preparations. There are many types of cows. We will refer to 
the Indian cow. Cow urine has many medicinal properties, vitamins, enzymes and 
bio-active substances that aid in treating many diseases.  
The Main Elements of Cow Urine and Their Functions: 
Many useful elements have been found in urine. Some of them are as below:  
Urea: 
         Urea is a major element found in urine and is the end product of protein 
metabolism. It is strong antibacterial agent. 
Uric acid: 
         Uric acid is similar to Urea and has strong antibacterial properties. In 
addition it helps to control cancer-causing substances. 
Minerals: 
        Minerals from urine can be very easily reabsorbed as compared to those 
derived from food. Urine probably contains more different types of minerals than 
those derived from food. Urine becomes turbid if left alone for a while This is 
because when enzyme present in urine dissolve urea and change it into ammonia 
then urine becomes strongly alkaline making it difficult to dissolve rich minerals. 
Therefore stale urine looks turbid this does not mean that it has decayed Urine 
with higher ammonical disorder content when applied to the skin plays an 
important role in beautifying it. 
Bioactive substance and hormones 
Urokinase: Dissolves blood clots, helps in curing heart diseases and improves 
blood circulation. 
Epithelium growth factor: Helps, repair and regenerate damaged tissues and 
cells.  
Colony stimulating factor: It is effective for cell division and multiplication. 
Growth hormone: Shows different bioactive effects such as promotion of protein 
production, cartilage growth, and fat decomposition. 
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Erythropoetine: Promotes production of red blood cells. 
Gonadotropins: Promotes normalization of menstrual cycle and sperm production 
Kallikrin: -Releases kallidin that expands peripheral veins and reduce blood 
pressure. 
Tripsyn inhibitor: Effective for prevention and healing of muscular tumour. 
Allantoine: Heals wounds and tumours. 
Anti-cancer substance: Anti-neoplaston, H-11 beta-iodole-acetic acid, directine, 
3-methyl gloxal, etc. differ from chemotherapeutic drugs, which kill or injure all 
kinds of cells. They strongly prevent the multiplication of carcinogenic cells and 
return them to normal. 
Nitrogen: It is diuretic & stimulates kidney naturally. 
Sulphur: It increases intestinal peristalsis and purifies blood. 
Ammonia:It maintains integrity of body tissues and blood. 
Copper: It checks excessive deposition of fat. 
Iron: It maintains RBC counts in blood and stabilizes stamina. 
Phosphate: It has litlhotriptic action. 
Sodium: It purifies the blood and checks hyperacidity. 
Potassium: It is appetizer and climinatcs muscle fatigue. 
Magnese: It is antibacterial and prevents gas gangrene. 
Carbolic Acid: It is antibacterial and prevents gas gangrene. 
Calcium: It purifies blood & provides nutrition to bones; helps in coagulation of 
blood. 
Salts: Antibacterial, Prevents Comma, and kctoacidois. 
Vitamin A, B, C, D, E: They prevent excessive thirst, infuses vigour, and increase 
potency. 
Lactose Sugar: Gives strength to heart, checks excessive thirst and giddiness. 
Enzymes: Improve immunity, and promote the secretion of digestive juices. 
Water; Controles the body temperature maintains the fluidity of blood. 
Hippuric Acid: Excrete toxins through the urine. 
Creatinine: It is antibacterial. 
Swama Kshar: Antibacterial, improves immunity, and acts as an antidote. 
Some hormones presents in 8-month pregnant cow which are very good for 
health
14
. 
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 RESEARCH ARTICLES PUBLISHED IN JOURNALS: 
1. Review Article Benefits of Cow Urine – A Review 25  
Sahu Rekha, Lalchand, G1upta Rakshapal and Rout OmPrakash 
 ABSTRACT: 
The  Cow  urine  has  been  used from  ancient  times  for  curing  many  
ailments  of  human beings.  It is important and essential part of PanchgavyaChikitsa. 
DiffferntAyurvedic  literature  have  mentioned its  importance  and  uses  for  
treatment  of,  Kushtha,  Kandu,  Udarrog,  Colic,  Abdominal  tumour, Enlargement  
of  the  abdomen  and  Flatulence,  for  therapies  such as  decoction  purgation,  
enema etc. Many researches  have  also  be  done,  which  shows  its  use  for  
treatment  of    Skin diseases,  Stomach diseases,  kidney  diseases,  Heart  diseases, 
Stones,  Diabetes, Liver  problem, Jaundice,  Athletes feet, cyst, Hemorrhoid  etc. and 
show  its Immunostimulant, Bioenhencer,  Anticonvulsant, Anti cancerous, Wound  
healing,  Antioxidant  and  Antimicrobial  properties.  It is also useful in agriculture 
forpreparation ofvermicompost and biopesticides. This review article will collect all 
the qualities and uses of Cow urine from different Ayurvedicand modern literature.  
The article will also collect the data from all researches done on Cow urine. Cow 
urine is excellent bioenhencer and recently Cow urine distillate has been granted U.S. 
patents. Further researches are required to prove its qualities and benefits. Public 
awareness is required to promote the importance and wide applications of cow urine 
to improve their health and lifestyle. 
2. Chemotherapeutic potential of cow urine: A review
26
 
GurpreetKaur Randhawa and Rajiv Sharma 
ABSTRACT 
In the grim scenario where presently about 70% of pathogenic bacteria are 
resistant to at least one of the drugs for the treatment, cue is to be taken from 
traditional/indigenous medicine to tackle it urgently. The Indian traditional knowledge 
emanates from ayurveda, where Bosindicus is placed at a high pedestal for numerous 
uses of its various products. Urine is one of the products of a cow with many benefits 
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and without toxicity. Various studies have found good antimicrobial activity of cow’s 
urine (CU) comparable with standard drugs such as ofloxacin, cefpodoxime, and 
gentamycin, against a vast number of pathogenic bacteria, more so against Gram-
positive than negative bacteria. Interestingly antimicrobial activity has also been 
found against some resistant strains such as multidrug-resistant (MDR) Escherichia 
coli and Klebsiellapneumoniae. Antimicrobial action is enhanced still further by it 
being an immune-enhancer and bioenhancer of some antibiotic drugs. Antifungal 
activity was comparable to amphotericin B. CU also has anthelmintic and 
antineoplastic action. CU has, in addition, antioxidant properties, and it can prevent 
the damage to DNA caused by the environmental stress. In the management of 
infectious diseases, CU can be used alone or as an adjunctive to prevent the 
development of resistance and enhance the effect of standard antibiotics. 
3. Evaluation of antidiabetic, antioxidant effect and safety profile of 
gomutra ark in Wistar albino rats
27
 
Devender O. Sachdev, Devesh D. Gosavi, and Kartik J. Salwe 
ABSTRACT 
The effect of Gomutra ark (GoA) on experimental alloxan-induced diabetes in 
rats was studied. For this purpose, Wistar albino rats of either sex weighing 200-250 g 
were used. The biochemical parameters like blood sugar, vitamin C, and 
malondialdehyde release were measured. The safety profile of GoA was evaluated 
using acute and chronic toxicity studies. GoA significantly lowers blood glucose in 
diabetic rats although the observed effect was found to be less than glibenclamide. It 
significantly lowers the level of malondialdehyde and vitamin C in diabetic rats. No 
toxicity was observed even when cow urine was given 32 times of the study dose in 
acute toxicity and no significant changes were seen when it was used chronically, 
which suggests that cow urine is having a very high therapeutic index. This study 
supports the traditional use of GoA in diabetes and is having a high therapeutic index 
and is safe for chronic use. However, further studies are needed to elucidate the 
mechanism of action of Gomutra ark. 
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4. Clinical Evaluation of Cow-Urine Extract special reference to 
Arsha (Hemorrhoids)
28
 
Dr.Omaprakash W.Talokar, Dr.Archana R. Belge, Dr.Raman S. Belge 
ABSTRACT:  
There are various traditional healing practices in India including Herbal 
therapies and other forms of alternate therapies which are non-clinical. Based on 
certain traditional and Ayurvedic point of view, consumption of Gomutra (Cow-
Urine) is a traditional remedy for various health conditions e.g. Arsha (Hemorrhoids). 
Cow-urine therapy is an ancient therapy part of Ayurveda. Cow-urine tries to balance 
the bodyelementsby re-establishing the equilibrium for a healthy body.Hemorrhoids 
are a common anorectal condition defined as the symptomatic enlargement and distal 
displacement of the anal mucosa. An inflammatory reaction and vascular hyperplasia 
may be present in Hemorrhoids. The present research paper deals with the oral 
supplementation of Cow-urine in hemorrhoids patients, which has prevented the time-
consuming, painful and expensive complications of Hemorrhoids. 
 
5. Clinical Trial of Gomutra (Cows Urine) In Obesity Management
29
 
Naveen Kumar Saini 
ABSTRACT 
The current research paper describes the importance of Gomutra (cow’s urine) 
in obesity management. For this purpose 30 patients were selected randomly from 
M.M.M Government Ayurvedic College & Associated Group of hospitals, Udaipur. 
For diagnostic purpose objective parameters like total body weight of patient, BMI, 
Measurement of skin-fold thickness, Circumference of Chest, Abdomen, Hip, Mid-
thigh, biochemical analysis like lipid profile and subjective parameters like Chalatva, 
KshudraSwasaDaurbalya,AngaGaurva,Alasya, Gatrasada, AlpaVyavaya, AtiKshudha, 
AtiPiapasaNidradhikya, Swedadhikya, Daurgandhya, Snigdhangta, Sandhishool were 
taken in to consideration. In pathogenesis of Sthaulya,Kapha (KledakaKapha), Vata 
(Samana&VyanaVayu),Meda (fat/lipid) and MedodhatvagniMandyata are main 
responsible factors according to our samhitas My hypothesis for this evaluation was 
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based on the facts that Gomutra has all those properties which can be helpful in 
Sampraptivighatana of obesity i.e.mTikshna, Ushna, Laghu and Kaphavatshamak etc. 
I also considered the biochemical analysis on Gomutra and its elemental properties. 
Keeping this in mind Gomutra was given to every patient according to their age and 
Kosthagni ranging from 3ml to 5ml with water and all changes were calculated by 
parameteric and non parameteric tests. In this study cows urine proved very effective 
in obesity management reduced weight and B.M.I by 6.51% and 6.11% respectively. 
This research is very important in today’s life because the problem of obesity is 
increasing day by day due to our sedentary life style and it is leading to very fatal 
diseases. 
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3. PIPER BETLE 
Classification: 
Kingdom : Plantae 
Clade  : Angiosperms 
Clade  : Magnoliids 
Order  : Piperales 
Family  : Piperaceae 
Genus  : Piper 
Species : P. betle 
Binomial name: 
Piper betle 
The betel (Piper betle) is the leaf of a vine belonging to the Piperaceae family, 
which includes pepper and kava. Betel leaf is mostly consumed in Asia and elsewhere 
in the world by some Asian emigrants, as betel quid or in paan, with Areca nut and/or 
tobacco. 
In India and Sri Lanka a sheaf of betel leaves is traditionally offered as a mark 
of respect and auspicious beginnings. Occasions include, greeting elders at wedding 
ceremonies, New Year, offering payment to Ayurvedic physicians and astrologers 
where usually money and/or areca nut are kept on top of the sheaf of leaves and 
offered to the elders for their blessings. 
The betel plant is an evergreen perennial, with glossy heart-shaped leaves and 
white catkin. The betle plant originated in South and South East Asia. 
Names in different languages 
The betle leaf is known as Pan in Bengali and Paan in Urdu and Hindi, 
Tambula and Nagavalli in Sanskrit, and Tanbul in Persian. Some of the names in the 
regions in which it is consumed are: Mlou(Cambodian), Tamalapaku(Telugu), 
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Naagarvelnapaan (Gujarati), veelyadayele (Kannada), Vettila (Malayalam), 
Kun(Burmese), Plū (Mon), Malus (Tetum), Maluu (Khmer), Plū (Thai), Bulath 
(Sinhalese), Malu (Tokodede), Bileiy (Dhivehi), bulungsamat (Kapampangan), 
daunsirih (Malaysian), daunsirih/suruh (Indonesian), Kebui (Palauan), Pupulu 
(Chamorro), Ikmo (Tagalog), Gawed (Ilokano), and Trầu (Vietnamese), 
Gaweud/Gawed in (Kalinga), Buyo (Bikol). 
Etymology 
Betle, derived from the Tamil/Malayalam word vettila, via Portuguese. 
Usage and cultural significance 
The primary use of betle leaf is as a wrapper for the chewing of areca nut or 
tobacco where it is mainly used to add flavour. It may also be used in cooking, usually 
raw, for its peppery taste. 
Health effects 
Some reports may suggest that betle leaf by itself has adverse health effects, in 
part because of tannins delivered by the leaf and for reasons currently not fully 
understood. For example, one research paper studied chromosome damaging effect of 
betel leaf in human leukocyte cultures. These researchers report an increase in the 
frequency of chromatid aberrations when the leaf extract was added to cultures. 
Another scientific study from Japan indicates that the lab rats that ate a mixture of 
betel leaf and areca nuts all had severe thickening of the upper digestive tract whereas 
after undergoing a diet of betel leaves alone, only one laboratory rat ended up having 
a forestomach papilloma
30
. 
RESEARCH ARTICLES PUBLISHED IN JOURNALS: 
1. New chemical constituents from the Piper betle Linn. 
(Piperaceae)
31
 - AkhtarAtiya, BarijNayanSinha& Uma RanjanLal 
ABSTRACT 
The phytochemical investigation of chloroform extract from Piper betle var. haldia, 
Piperaceae, leaves has resulted in the isolation of two new chemical constituents which were 
identified as 1-n-dodecanyloxy resorcinol (H1) and desmethylenesqualenyldeoxy-
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cepharadione-A (H4), on the basis of spectroscopic data 1D NMR (1H and 13C) and 2D 
NMR (1H-1H COSY and HMBC) as well as ESI-MS, FT-IR and HR-ESI-MS analyses. 
Compounds H1 and H4 showed excellent antioxidant DPPH free radical scavenging activity 
with IC50 values of 7.14 μg/mL and 8.08 μg/mL compared to ascorbic acid as a standard 
antioxidant drug with IC50 value of 2.52 μg/mL, respectively. Evaluation of cytotoxic 
activity against human hepatoma cell line (PLC-PRF-5) showed moderate effect with the 
GI50 values of 35.12 μg/mL for H1, 31.01 μg/mL for H4, compared to Doxorubicin® as a 
standard cytotoxic drug with GI50 value of 18.80 μg/mL. 
2. Biotechnological intervention in betelvine (Piper betle L.): A 
review on recent advances and future prospects
33
 
SuryasnataDas, ReenaParida, I.SriramSandeep, SanghamitraNayak, 
SujataMohanty 
ABSTRACT 
Betelvine (Piper betle L.) is cultivated for its deep green heart shaped leaf for 
(15–20) million Indian and 2 billion foreign consumers annually. The crop provides 
Rs (6 000–7 000) million of national income per year and at the same time leaves 
worth Rs (30–40) million is exported to other countries. The leaves are not only used 
directly for chewing purposes but also possesses antioxidant, anti-inflammatory, anti-
apoptotic, anti-cancer and anti-microbial properties. Besides, the leaves also contain 
eugenol rich essential oil (1%–3%) which is the source for medicine, stimulant, 
antiseptic, tonic and other ayurvedic formulations. The essential oil also contains 
chavibetol, caryophyllene and methyl eugenol which are the potent source for 
preparation in ayurvedic medicine and herbal products. Cost of betelvine essential oil 
is 10$ per 5 mL. In spite of its great economical and medicinal importance betelvine 
is still neglected by the researchers for proper characterization and authentication for 
selection of elite landraces. Lack of awareness among people, use of same planting 
material for many generations, existing of many synonyms for a single landraces, no 
proper characterization of available landraces are some of the significant constraints 
for its commercialization. Our review endeavours a complete advance in the research 
on betelvine, existing lacunae for its proper characterization and commercial 
cultivation. It also attempts to provide a comprehensive account on biotechnological 
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interventions made in betelvine aimed at complementing conventional programmes 
for improvement of this nutraceutically important cash crop. 
3. A Review: Nutraceuticals Properties of Piper betel (Paan)
33
 
Ekta Singh Chauhan, Jaya Aishwarya*, Akriti Singh and AnamikaTiwari 
ABSTRACT 
Piper betel or Betel vine deep green heart shaped vary famous leaves belongs 
to the family Piperaceae called Paan leaves in India; rich in nutrients, minerals, 
vitamins, antioxidants, phytochemicals. Piper betel is mostly use to chew with sliced 
areca nut, slaked lime, coriander, aniseed, clove, cardamom, sweetener, coconut 
scrapings etc, but less used remedy. It is cultivated in hotter and damper part in 
country following the traditional methods in India on about 55,000 hectare with an 
annual production worth about Rs 9000 million. Focusing on traditional use and 
medicinal use of Piper betel we can cure many diseases and reduce the oral cancer 
which actually happens due to sliced areca nut, slaked lime not because of betel 
leaves. Leaves are rich in many nutrients like water, energy, protein, fats, fiber, 
calcium and iron etc. and the antioxidants present are flavonoids, tannins, saponins 
alkaloids, terpenoids etc. Piper betel helps in curing various diseases like diabetes, 
hypertension, brain toxin, halitosis, boils and abscesses, obesity, wound healing, voice 
problems, conjunctivitis, constipation, headache, hysteria, itches, mastitis, mastoiditis, 
leucorrhoea, otorrhoea, ringworm, swelling of gum, rheumatism, abrasion, cuts and 
injuries etc. So, we have to highlight these nutrients rich betel leaves and its benefits. 
This paper put a light on nutraceuticals properties of betel leaves and says that 
cultivation and use of betel leaves should be increased to cure the diseases. 
4. Pharmacognostic Study on the Leaf of Piper betle L.
34
 
Swe Mar Tin 
ABSTRACT 
Specimens were identified according to Hooker (1879), Kirtikar and Basu 
(1933), Backer (1963), Hutchinson (1967), Brandis (1971) and Dassanayake (1987). 
Fresh and powder leaves of Piper betle L. were studied with the methods of Wallis 
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(1967), Trease and Evans (1978) and Evans (2002). Elemental analysis was 
conducted by using Energy Dispersive X-Ray Fluorescence (EDXRF) and Atomic 
Absorption Spectrophotometery (AAS) methods. Piper betle L. contained the highest 
Mg concentration having 8.412 ± 0.007 ppm. Various solvents extracts of leaves 
showed the antimicrobial activity against Bacillus subtilis, Staphylococcus aureus, 
Pseudomonas aeruginosa, Bacillus pumalis, Candida albicans and Escherichia coli. 
Water extract of Piper betle L. showed activity against Bacillus subtilis respectively. 
5. Antioxidant and non toxic properties of Piper betle leaf extract: in 
vitro and in vivo studies
35
 
DharamainderChoudharyRaosaheb K. Kale 
ABSTRACT 
Piper betle leaves are used in folk medicine for the treatment of various 
disorders and is commonly chewed among Asians. The present study investigates the 
protective efficacy of P. betle leaf extract. The presence of the extract inhibited the 
radiation induced lipid peroxidation process effectively. This could be attributed to its 
ability to scavenge free radicals involved in initiation and propagation steps. Oral 
supplementation with extract (1, 5 and 10 mg/kg) was administered daily for 2 weeks 
to Swiss albino mice and the hepatic antioxidant status was analysed. The GSH 
content was enhanced and no appreciable change was found in the levels of oxidative 
damage in terms of lipid peroxidation. Also, the specific activity of SOD increased in 
a dose dependent manner. These factors indicate the elevation of antioxidant status in 
the animals. The effect on the glyoxalase system which is considered to be activated 
under stress conditions was also investigated. Our findings did not observe any 
significant change in gly I and gly II activities, implying a nonstress condition after 
oral treatment of the extract. The present study indicates the antioxidant activity of P. 
betle leaf extract and its potential to elevate the antioxidant status. 
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4. VITEX NEGUNDO 
Vitex negundo, commonly known as the Chinese chaste tree, Five- leaved 
chaste tree, or horseshoe vitex, is a large aromatic shrub with quadrangular, densely 
whitish, tomentose branchlets. It is widely used in folk medicine36. 
Other Names: 
Sans: Sephalika; Nirgundi; Svetasurasa; Vrikshaha; Sindhuvaram. 
Eng: Five-leaved Chaste Tree. 
Fr: Gattilierincise. 
Hind: Sambhalu; Sawbhalu; Nirgundi; Nisinda; Mewri. 
Ben: Nishinda; Nirgundi; Samalu. 
Bom: Katri; Nirgundi; Shiwari; Nirgunda; Nisinda. 
Mah: Nirgunda 
Gwalior: Nigad. 
Guj: Nagoda; Shamalic. 
Tel: Sindhuvaruma; Tellavavilli; Vavili; Nalla-vavili. 
Tam: Chinduvaram; Nirnochi; Nochchi; Notchi; Vellai-noch-chi. 
Mal: Indrani. 
Can: Bile-nekki. 
Burm: Kiyon-bhanbin. 
Pers: Pajankusut. 
Punj: Marwan; Maura; Banna; Torbanna; Swanjan; Mawa; Amalu(roots and 
leaves); Bari(fruit). 
Habitat: 
 Bengal, Southern India and Burma. 
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Parts used: Root, fruit, flowers, leaves and bark. 
Constituents:  
Leaves contain a colourless essential oil resin of the odour of the drug, and a 
resin; fruits contain an acid resin, as astringent organic acid, malic acid, traces of an 
alkaloid and a colouring matter.  
RESEARCH ARTICLES PUBLISHED IN JOURNALS: 
1. Evaluation of Phytochemical and Antimicrobial study of Extracts 
of Vitexnegundo Linn
37
 
GautamKeerti and Kumar Padma, Keertigautam 
ABSTRACT 
The persistent increase in the number of antibiotic resistant strains of 
microorganisms has led to the development of more potent but more expensive 
antibiotics. In most developing countries of the world these antibiotics are not readily 
affordable, thus making compliance difficult. This calls for research into alternative 
source of antimicrobials. Present work was carried out to assess the antimicrobial 
activity of V.negundo against some multidrug resistant pathogenic bacteria. 
V.negundo flower buds were collected, air dried and soxhlet extracted by using 
standard method for flavonoid extraction. These extracts were then tested for 
antimicrobial activity using disc diffusion method. MIC, MBC & TA was also 
calculated. Flower buds bound flavonoid extract of Vitex showed highest antibacterial 
activity (IZ=25mm, AI=1.38±0.026) against Bacillus subtilis and (IZ=25mm, 
AI=1.04±0.010) against Raoultellaplanticola. The minimum inhibitory concentration 
(MIC) of Vitex was 0.039 mg/ml against Bacillus subtilis, raoultellaplanticola and 
Agrobacterium tumifaciens. The most active extract of bound flavonoid of flower 
buds was analyzed by GCMS study, which revealed eighty compounds in it. Two 
flavonoids were found in the flowers buds of Vitexnegundo, as Kampferol-3-O-
rutinoside (RT=30.342) and 5-hydroxy- 3, 6, 7, 3’, 4’-pentamethoxy flavones 
(RT=49.408), that are not has been reported earlier in flower buds of Vitexnegundo. 
Flavonoids of flower buds extract of V.negundo Linn has the potential to be 
developed into an antimicrobial agent. 
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2. A Review of Ethnomedicinal Plant-Vitexnegundo Linn
38
 
FauziyaBasri, H.P. Sharma, SazyaFirdaus, Paras Jain and AlokRanjan 
ABSTRACT 
Vitexnegundo belongs to family Verbenaceae and grows as small tree with 
thin grey bark. The plant is widely distributed and also has pharmacological actions 
against wide spectrum of diseases in traditional system of medicines. All parts of the 
plant especially its leaves contain numbers of secondary metabolites such as alkaloids, 
phenols, flavonoids, glycosidicirridoids, tannins and terpenes. Because of the richness 
in phytochemicals, the plant is attributed to possess a number of therapeutic uses; 
antimicrobial, antiinflammatory, astringent, bronchodilator, CNS-depressant, 
detoxicant, diuretic, emmenagogue, anticancer and hepatoprotective etc. It is also 
used as repellent, insecticide and larvicidal. Leaf extract is employed as nervinetonic, 
tranquilizer and vermifuge. This review aims at presenting comprehensive 
information on phytochemical constituents and therapeutic uses which can be helpful 
in development of modern medicine. 
3. Anti-Amnesic Activity of VitexNegundo in Scopolamine Induced 
Amnesia in Rats
39
 
Abhinav Kanwall, Jogender Mehla, MadhusudanaKunchal, Vegi Ganga 
ModiNaidul, Yogendra Kumar Gupta, Ramakrishna Sistla 
ABSTRACT 
  In the present study we investigated the anti-amnesic activity of Vitexnegundo 
in scopolamine induced amnesia in rats. Wistar rats (180-200g) were trained on active 
avoidance task .Each animal received session of 15 trials with inter trial duration of 
15s for 5 days. Scopolamine (3mg/kg, i.p) was administered at different time periods 
on the basis of stages of memory i.e acquisition, consolidation and retention in 
different groups (n= 6). Effect of Vitexnegundo extract was evaluated and compared 
to a standard drug, Donepezil. Significant (p< 0.05) increase in the avoidance 
response on the 5
th
session has been observed as compared to1st session in control 
group. Scopolamine treatment significantly (p< 0.05) reduced the avoidance response 
compared to control.Extract treated groups shown significant (p< 0.05) in-crease in 
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number of avoidance responses as compared to scopolamine treated groups. Increased 
oxidative stress in brain after scopolamine treatment, as observed by increase in MDA 
& decrease in GSH & SOD, was lowered in the groups treated with extracts. AChE 
activity was also improved after V.negundo treatment. Results of the study have 
shown that V.negundo treated groups decrease the phenomenon of amnesia by 
increasing learning of memory through antioxidant effect and decreasing AChE 
activity. 
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5. ALOE VERA 
Classification:  
Kingdom : Plantae 
Clade  : Angiosperms 
Clade  : Monocots 
Order  : Asparagales 
Family  : Asphodelaceae 
Subfamily :  Asphodeloideae 
Genus  : Aloe 
Species : A. vera 
Binomial name: 
Aloe vera 
Synonyms: 
Aloe barbadensis Mill. 
Aloe barbadensis var. chinensis Haw. 
Aloe vera is a succulent plant species of the genus Aloe. An evergreen 
perennial, it originates from the Arabian Peninsula but grows wild in tropical climates 
around the world and is cultivated for agricultural and medicinal uses. The species is 
also used for decorative purposes and grows successfully indoors as a potted plant. 
It is found in many consumer products including beverages, skin lotion, 
cosmetics, or ointments for minor burns and sunburns. There is little scientific 
evidence of the effectiveness or safety of Aloe vera extracts for either cosmetic or 
medicinal purposes. Studies finding positive evidence are frequently contradicted by 
other studies. 
 Preclinical Safety Evaluation of Mandura Chenthooram Page 47 
 
Aloe vera leaves contain phytochemicals under study for possible bioactivity, 
such as acetylated mannans, polymannans, anthraquinone C-glycosides, anthrones, 
other anthraquinones, such as emodin and various lectins. 
Uses: 
Research: 
There is little scientific evidence of the effectiveness or safety of Aloe vera 
extracts for either cosmetic or medicinal purposes. A research study finding positive 
evidence is frequently contradicted by other studies. 
Despite this, the cosmetic and alternative medicine industries regularly make 
claims regarding the soothing, moisturizing, and healing properties of aloe vera. 
Two 2009 reviews of clinical studies determined that all were too small and 
faulty to allow strong conclusions to be drawn. One of the reviews found that Aloe 
has not been proven to offer protection for humans from sunburn. 
There is no good evidence aloe vera is of use in treating wounds or burns.  
There is no good evidence that topical application of aloe vera is effective for treating 
genital herpes or psoriasis. A 2014 Cochrane review found no strong evidence for the 
value of topical application of aloe vera to treat or prevent phlebitis caused by 
intravenous infusion. 
Aloe vera gel is used commercially as an ingredient in yogurts, beverages, and 
some desserts, although at certain high doses, its toxic properties could be severe 
whether ingested or topically applied. The same is true for aloe latex, which was taken 
orally for conditions ranging from glaucoma to multiple sclerosis until the FDA 
required manufacturers to discontinue its use. 
Dietary supplement: 
Aloin, a compound found in the exudate of some Aloe species, was the 
common ingredient in over-the-counter (OTC) laxative products in the United States 
until 2002 when the Food and Drug Administration banned it because the companies 
manufacturing it failed to provide the necessary safety data. Aloe vera has potential 
toxicity, with side effects occurring at some dose levels both when ingested and 
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applied topically. Although toxicity may be less when aloin is removed by processing, 
Aloe vera that contains aloin in excess amounts may induce side effects. 
Aloe vera juice is marketed to support the health of the digestive system, but 
there is neither scientific evidence nor regulatory approval to support this claim. The 
extracts and quantities typically used for such purposes appear to be dose-dependent 
for toxic effects. 
Traditional medicine: 
Aloe vera is used in traditional medicine as a skin treatment. In Ayurvedic 
medicine it is called kathalai, as are extracts from agave. For aloe for agave early 
records of Aloe vera use appear in the Ebers Papyrus from the 16th century BC, and 
in Dioscorides' De MateriaMedica and Pliny the Elder's Natural History – both 
written in the mid-first century AD. It is also written of in the Juliana Anicia Codex of 
512 AD. The plant is used widely in the traditional herbal medicine of many 
countries. 
Commodities: 
Aloe vera is used on facial tissues where it is promoted as a moisturizer and 
anti-irritant to reduce chafing of the nose. Cosmetic companies commonly add sap or 
other derivatives from Aloe vera to products such as makeup, tissues, moisturizers, 
soaps, sunscreens, incense, shaving cream, or shampoos. A review of academic 
literature notes that its inclusion in many hygiene products is due to its "moisturizing 
emollient effect". 
Other potential uses for extracts of Aloe vera include the dilution of semen for 
the artificial fertilization of sheep, as a fresh food preservative, or for water 
conservation in small farms.It has also been suggested that biofuels could be obtained 
from Aloe vera seeds. 
Toxicity: 
Under the guidelines of California Proposition, orally ingested non-
decolorized aloe vera leaf extract has been listed by the OEHHA, along with 
goldenseal, among "chemicals known to the state to cause cancer or reproductive 
toxicity". 
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Use of topical aloe vera is not associated with significant side effects. Oral 
ingestion of aloe vera, however, may cause abdominal cramps and diarrhea which in 
turn can decrease the absorption of drugs. IARC studies have found ingested non-
decolorized liquid aloe vera to be carcinogenic in animals, and state that it is a 
possible carcinogen when eaten or ingested by humans as well. 
RESEARCH ARTICLES PUBLISHED IN JOURNALS: 
1. Recent update on the medicinal properties and use of Aloe vera in 
the treatment of various ailments
41
 
Gajendra Mahor and Sharique A Ali 
ABSTRACT 
Aloe vera (Aloe barbadensis) an herb is widely used in Ayurvedic, 
Homoeopathic and Allopathic streams for its marvelous medicinal properties. This 
plant is one of the richest natural sources of health for mammals including human 
beings. The chemistry of the plant has revealed the presence of more than 200 
different biologically active substances, which include antimicrobial, antibacterial, 
antifungal, antiviral, activities of the nonvolatile constituents of the leaf 
gel. Aloe species are widely distributed in the African and the eastern European 
continents, and are spread almost throughout the world. The genus Aloe has more 
than 400 species but few, such as A. Vera, Aloe ferox, and Aloe arborescens, are 
globally used for trade. Many biological properties associated with Aloe species are 
contributed by inner gel of the leaves. anti diabetic, anti-inflammatory, peptic ulcers, 
antitumor, anticancer Properties, activity effects on the Immune System, adverse 
reactions, Laxative effects, wound healing, antiseptic, vitamins, minerals, enzymes, 
amino acids, stress, sugars. It is known to help slow down the appearance of wrinkles 
and actively repair the damaged skin cells that cause the visible signs of aging. Aloe is 
a powerful detoxifier, antiseptic and tonic for the nervous system. Aloe vera gel 
contains a large range of vitamins even vitamin B12, Vitamin A, contains B-Group 
vitamins, Vitamin C, Vitamin E and folic acid. Aloe vera gel contains important 
ingredients including 19 of the 20 amino acids needed by the human body and seven 
of the eight essential ones that just cannot be made. The plantleaves and inner gel 
contains numerous help it has potential to cure sunburns and minor cuts, and even 
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skin cancerandacts as also acts as extremely powerful laxative. Various parts of the 
plant have different effects on the body. The present review is an attempt to highlight 
the proven research related botanical and pharmacological medicinal properties of 
Aloe vera. 
2. Aloe vera their chemicals composition and applications: A review  
Sharrif Moghaddasi M, Sandeep Kumar Verma
42
 
ABSTRACT: 
It was known to people in Egypt and also Greece for example 
Aristotelesexplains specialcharactristics of Aloe verajelatin that is extracted from this 
plant is continuously used to treat burns, cuts and inflamed scars since many years. It 
is useful for skin damaged from X ray as reported in many   researches in journals 
related x rays. On the other hand concentration of glucose ingelatin, results in high 
osmotic presure, that protect skin from live bacteria. Aloe vera includes ''Antrokinon'' 
cemicals   that are known as anti virus, anti bacteria and anti cancer. Aloe vera (Aloe 
vera) has 400 species but just 2 species; A.barbadensisare used for trade in the world. 
This plant need very less water for living and also can survive on saline soils, beaches 
and is resistance to diseases and insects. It can live in very hot regions, but cannot 
tolerate cold. Aloe vera grows in, Mexico, India, South and centeral America, Africa, 
Australia, Carribians and Iran. This paper reviews history, its chemicals, medical 
usage, plant morphology, extracts and agronomy of Aloe vera. 
 
                  Materials And Methods 
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4. MATERIALS & METHODS 
4.1. Selection of the drug: 
The test drug Mandura Chenthooram was selected for the evaluation of 
toxicity studies in wistar albino rats. 
Ingredients: 
 Manduram (Ferroso ferric oxide or Iron oxide)   
 Koneer (Cow’s urine)  
 Vettrilai charu (Piper betle juice)  
 Notchiilai charu (Vitex negundo juice)  
 Vellattu paal   (Goat milk)  
 Vellattu neer (Goat urine)  
 Kumari charu (Aloe vera)1 
                           
                        MANDURAM                                          PASUNEER 
           (COW URINE) 
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VETRILAI                                   NOTCHI 
 
            
 
VELLATTUNEER                                       VELLATTUPAAL 
(GOAT URINE)                                      (GOAT MILK) 
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KATRAZHAI 
 
 
  
 
 
 
PREPARATION 
OF 
THE DRUG 
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4.2. COLLECTION, AUTHENTICATION, PURIFICATION AND 
PREPARATIO OF THE TEST DRUG: 
Collection: 
Manduram (Ferroso ferric oxide) was procured from a well reputed country 
shop in chennai. The following herbal drugs such as Vettrilai (Piper betle), Katrazhai 
(Kumari-Aloe Vera) procured from Tambaram market, Chennai. Then Notchi (Vitex 
negundo) collected from NIS Campus Chennai. Pasuneer (Cow urine), Vellattuneer 
(Goat urine), Vellattupaal (Goat milk) were collected from village in Paruvakkudi. 
Identification and Authentication of the raw drug: 
The herbal drugs were identified and authenticated by from the department of 
Medicinal Botany, NIS Tambaram sanatorium, Chennai. (Certificate no: 
NISMB2822017, 06.03.2017). The metal drug was identified and authenticated by 
from the Department of Gunapadam, NIS, Tambaram Sanatorium, Chennai. 
(Certificate no: F.No:NIS/Gunapadam/Au/2017/5, 03.04.2017).  
Purification: 
          Hot flame the 3 palams of manduram in the kannan ulai. Dip the flamed 
manduram 7 times in Pasuneer (cow’s urine). Then wash with water and dry it. Grind 
the dried manduram and keep it in katra. Pour Vetrilai charu (juice) in katra above the 
level of dried manduram and keep it in sunlight for 3 days by maintaining the juice 
level. Then pour Notchiilai charu (Vitex negundo leaf juice), Vellattupaal (Goat 
milk), Vellattuneer (Goat’s urine) one by one like Vetriali charu (juice)1. 
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UNPURIFIED MANDURAM 
 
 
 
AT THE TIME OF PURIFICATION PROCESS 
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AFTER PURIFICATION 
 
 
Preparation of Mandura Chenthooram: 
Grind purified Manduram with aloe vera juice for 4 samams (12hrs) and make 
it into one villai. Dry it in sunlight and put it in a small agal (Pot) cover with suitable 
agal and tightly sealed with seelai. Use 50 dried cow dung, for the pudam. After the 
pudam has done, open the seelai and look for red colour which is the indication for 
better finishing of medicine. Then grind the medicine with aloe vera juice for 4 
samams when attaining the mezhughu patham, make villai and dry it in sunlight. 
Place the dried villai in agal and tightly sealed with seelai. Again pudam has done 
using 50 dried cow dung
1
.  
 
 
 
 
 
KATRAZHAI CHARU (KUMARI CHARU) 
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MANDURA CHENTHOORAM 
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Therapeutic dose: 
The dose is equivalent to 1/2 - 1 kuntri (65-130mg), twice daily after 
food.The duration of treatment is 10-12 days. 
Adjuvent: 
As per literature Mandura Chenthooram is administered along with honey.  
Therapeutic uses:   
 Anaemia(Paandu),  
 Dropsy(Sobai),  
 Jaundice(Kaamalai),  
 Ascites(Peruvayiru),  
 Cough(Eelai),  
 Diarrhoea (Kirani).  
It improves the Hemopoisis
1
.   
 
  
 
 
 
QUALITATIVE ANALYSIS 
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STANDARDIZATION OF MANDUARA CHENTHOORAM  
4.3. QUALITATIVE ANALYSIS: 
I. PHYSICO-CHEMICAL ANALYSIS OF – MANDUARA CHENTHOORAM 
The physico- chemical properties of Mandura Chenthooram is carried as per 
Standard procedure at The Tamilnadu Dr.M.G.R.Medical University, Guindy, 
Chennai. 
1. Loss on Drying: 
  An accurately weighed 2g of Mandura Chenthooram formulation was taken 
in a tarred glass bottle. The crude drug was heated at 105
0
C for 6 hours in an oven till 
a constant weight. The Percentage moisture content of the sample was calculated with 
reference to the shade dried material. 
2. Determination of total ash: 
  Weighed accurately 2g of Mandura Chenthooram formulation was added in 
crucible at a temperature 600
0
C in a muffle furnace till carbon free ash was obtained. 
It was calculated with reference to the air dried drug. 
3. Determination of acid insoluble ash: 
Ash above obtained, was boiled for 5min with 25ml of 1M Hydrochloric acid 
and filtered using an ash less filter paper. Insoluble matter retained on filter paper was 
washed with hot water and filter paper was burnt to a constant weight in a muffle 
furnace. The percentage of acid insoluble as calculated with reference to the air dried 
drug. 
4. Determination of water soluble ash: 
Total ash 1g was boiled for 4min with 25ml water and insoluble matter 
collected on an ash less filter paper was washed with hot water and ignited for 15 min 
at a temperature not exceeding 450
0
C in a muffle furnace. The amount of soluble ash 
is determined by drying the filtrate. 
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5. Determination of water soluble Extractive: 
  5gm of dried drug, coarsely powdered Mandura Chenthooram was 
macerated with 100ml of distilled water in a closed flask for twenty- four hours, 
shaking frequently. The solution was filtered and 25 ml was evaporated in a tarred flat 
bottom shallow dish, further dried at 100
0
C and weighted. The percentage of water 
soluble extractive was calculated with reference to the air dried drugs. 
6. Determination of alcohol soluble Extractive: 
  2.5gm. of air dried drugs; coarsely powdered Mandura Chenthooram was 
macerated with 50 ml. Alcohol in closed flask for 24 hrs. With frequent shaking, it 
was filtered rapidly taking precaution against los of alcohol. 10ml of filtrate was then 
evaporated in a tarred flat bottom shallow dish, dried at 100
0
C and weighted. The 
percentage of alcohol soluble extractive was calculated with reference to air dried 
drug.  
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II. BIO-CHEMICAL ANALYSIS: 
The bio-chemical analysis of Mandura chenthooram as done at Biochemistry lab 
National Institute of Siddha, Chennai-47. 
S.NO EXPERIMENT OBSERVATION 
1. Appearance of the sample   Dark red in colour 
2. Solubility: 
 
A little of the sample is shaken well with 
distilled water 
 
 
 
Sparingly soluble 
3. Action of heat: 
 
A small amount of the sample is taken in 
a dry test tube and heated gartly at first 
and then strong. 
 
 
 
White fumes evolved 
4. Flame test: 
 
A small amount of the sample is made 
into a paste with con.HCL in a watch 
glass and introduced into non luminous 
part of the Bunsen flame. 
 
 
 
Bluish green flame not 
appeared. 
5. Ash test: 
 
A filter paper is soaked into a mixture of 
sample and cobalt nitrate solution and 
introduced into the Bunsen flame and 
ignited 
 
 
 
No yellow colour flame 
 
 
Preparation of extract: 
5 gm of Mandura Chenthooram is weighed accurately and placed in a 250ml 
clean beaker and added with 50 ml of distilled water. Then it is boiled well for about 
10 minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up to 
100ml with distilled water. 
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I. Test for Acid Radicals: 
S.NO EXPERIMENT OBSERVATION 
1. Test for sulphate: 
 
2ml of the above prepared extract is taken in a 
test tube to this added 2ml of 4% ammonium 
oxalate solution. 
 
 
 
Cloudy appearance 
present. 
2. Test for chloride: 
 
2ml of the above prepared extract is added 
with diluted HNO3 till the effervescence 
ceases. Then 2 ml of silver nitrate solution is 
added. 
 
 
 
No cloudy appearance 
present. 
3. Test for phosphate: 
 
2ml of the extract is treated with 2ml of 
ammonium molybdate solution and 2ml of 
con. HNO3. 
 
 
 
No cloudy yellow 
appearance present. 
4. Test  for carbonate: 
 
2ml of the extract is treated with 2ml 
magnesium sulphate solution. 
 
 
 
Cloudy appearance 
present. 
5. Test for sulphide: 
 
1gm of the substance is treated with 2ml of 
con HCL. 
 
 
 
 
 
No rotten egg smelling gas 
evolved. 
6. Test for Fluoride and oxalate: 
 
2ml of extract is added with 2ml of dil.Acetic 
acid and 2ml calcium chloride solution and 
heated. 
 
 
 
No cloudy appearance. 
7. Test for nitrite: 
 
3 drops of the extract is placed on a filter 
paper, on those 2drops of acetic acid and 2 
drops of benzidine solution is placed.  
 
 
 
No characteristic changes. 
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8. Test for borate: 
 
2 pinches of the substance is made into paste 
by using sulphuric acid and alcohol (95%) and 
introduced into the blue flame. 
 
 
 
Bluish green colour flame 
not appeared. 
 
II. Test for basic radicals: 
1. Test for lead: 
 
2ml of the extract is added with 2ml of 
potassium iodide solution. 
 
 
 
No yellow precipitate is 
obtained. 
2. Test for copper: 
 
One pinch of substance is made into paste 
with con HCL in a watch glass and introduced 
into the non luminuouspart of flame. 
 
 
 
No Blue colour flame not 
appeared. 
3. Test for aluminium: 
 
2ml of the extract sodium hydroxide is added 
in drops to excess. 
 
 
 
 
 
No Characteristics 
changes. 
4. Test for iron: 
 
2ml of extract add 2ml of ammonium 
thiocyanate solution and 2ml of con HNO3 is 
added. 
 
 
 
Blood red colour appeared 
5. Test for zinc: 
 
2ml of the extract sodium hydroxide solution 
is added in drops to excess. 
 
 
 
No White precipitate is 
formed. 
6. Test for calcium: 
 
2ml of the extract is added with 2ml of 4% 
ammonium oxalate solution. 
 
 
 
Cloudy appearance and 
white precipitate obtained. 
7. Test for magnesium: 
 
2ml of extract sodium hydroxide solution is 
added in drops to excess. 
 
 
 
No White precipitate is 
obtained. 
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8. Test for ammonium: 
 
2ml of extract few ml of Nessler’s reagent and 
excess of sodium hydroxide solution are 
added. 
 
 
 
No brown colour 
appeared. 
9. Test for potassium: 
 
A pinch of substance is treated with 2ml of 
sodium nitrite solution and then treated with 
2ml of cobalt nitrate in 30% glacial acetic 
acid. 
 
 
 
No yellowish precipitate is 
obtained. 
 
10. Test for sodium: 
 
2 pinches of the substance is made into paste 
by using HCL and introduced into the blue 
flame of Bunsen burner. 
 
 
 
No yellow colour flame 
appeared. 
11. Test for mercury: 
 
2ml of the extract is treated with 2ml of 
sodium hydroxide solution. 
 
 
 
No yellow precipitate is 
obtained. 
 
12. Test for arsenic: 
 
2ml of the extract is treated with 2ml of 
sodium hydroxide solution 
 
 
No brownish red 
precipitate is obtained. 
 
 
III. Miscelloneus: 
1. Test for starch: 
 
2ml of extract is treated with weak iodine 
solultion. 
 
 
 
Sky blue colour 
developed. 
 
      2. 
 
Test for reducing sugar: 
 
5ml of benedict’s qualitative solution is taken 
in a test tube and allowed to boil for 2 minutes 
and added 8 to 10 drops of the extract and 
again boil it for 2 minutes. The colour changes 
are noted. 
 
 
 
 
No brick red colour 
developed. 
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3. Test for the alkaloids: 
 
a. 2ml of the extract is treated with 2ml of 
potassium iodide solution. 
 
b. 2ml of extract is treated with 2ml of picric 
acid. 
 
c. 2ml of the extract is treated with 2ml of 
phosphor tungstic acid. 
 
 
 
 
 
 
Yellow colour developed. 
4. Test for tannic acid: 
 
2ml of extract is treated with 2ml of ferric 
chloride solution. 
 
 
 
No black precipitate is 
obtained 
5. Test for unsaturated compound: 
 
2ml of extract 2ml of potassium permanganate 
solution is added. 
 
 
 
Potassium permanganate is 
not decolourised. 
6. Test for amino acid: 
 
2 drops of the extract is placed on a filter 
paper and dried well. 
 
 
 
Not violet colour 
developed. 
7. Test for type of compound: 
 
2ml of the extract is treated with 2ml of ferric 
chloride solution. 
 
 
 
Red colour developed. 
 
 
 
 
 
 
 
 
  
 
 
 
 
SPECTROSCOPIC ANALYSIS 
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4.4. SPECTROSCOPIC ANALYSIS 
1. ATOMIC ABSORBTION SPECTROMETER (AAS): 
Mandura Chenthooram was analyzed in the presence of heavy metals by using 
ATOMIC ABSORBTION SPECTROMETER (AAS). This study was done at 
Asthagiri Herbal Research Fountation, 162-A, Perungudi Industrial Estate, Perungudi, 
Chennai-96. 
 INSTRUMENT DETAILS:  
UV-Vis spectrometer AA240 series, UV 8500 Absorption Spectrometer 
(AAS) was used for the analysis. The operating parameters:  
 Instrument technique                    : UV Method  
 Wavelength (Iron)                         : 248.3nm  
The hollow cathode lamp for Fe was used as a light source to provide wavelength for 
the elements to be determined. 
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2. INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION 
SPECTROMETRY (ICP-OES): 
The analysis of heavy metals and trace elements were estimated by using  
Inductively Coupled Plasma Optical Emission Spectrometry (ICP- OES).  The  
Experimental Procedure was done at SAIF, IIT Madras, Chennai-36. 
INTRODUCTION: 
Inductively coupled plasma optical emission spectrometry (ICP-OES), is an 
analytical technique used for the detection of trace metals. It is a type of emission 
spectroscopy that uses the inductively coupled plasma to produce excited atoms and 
ions that emit electromagnetic radiation at wavelength characteristic of a particular 
element. The intensity of this emission is inductive of the concentration of the element 
within the sample. 
PRINCIPLE: 
A Perkin-Elmer Optima ICP spectrometer is used for routine ICP-OES 
analysis. First, a high-energy radio frequency field is impinged upon a stream of 
argon gas. Then, a spark is used to ionize the argon gas, which forms sustained 
plasma due to inductive coupling with the high energy radio frequency field and the 
continuous supply of fresh argon to the plasma torch. This plasma has solutions 
passed into it in the form of a fine aerosol. The aerosol is dried, the dried particles 
broken apart, and the individual elements are excited by interaction with the excited 
state argon in the plasma. As each atom returns to its ground state from the excited 
state, they emit light at wavelengths characteristic of the elements from which they 
originate. The emission intensity for each element is monitored for versus element 
concentration can be constructed. 
EXTRACTION OF INFORMATION: 
Obtaining qualitative information, i.e., what elements are present in the 
sample, involves identifying the presence of emission at the wavelengths 
characteristic of the elements of interest. Obtaining quantitative information, i.e., how 
much of an element is in the sample, can be accomplished using plots of emission 
intensity versus concentration called curves. 
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Perkin-Elmer Optima 5300DV 
Rf frequency 40 M Hz 
Range 165-782 nm 
Detection limit Upto ppm level using SCD detector 
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3. X-RAY POWDER DIFFRACTION (XRD):                                               
                                    
X-ray powder diffraction (XRD) is a rapid analytical technique primarily used 
for phase identification of a crystalline material and can provide information on unit 
cell dimensions. The analysed material is finely ground, homogenized, and average 
bulk composition is determined.  
Crystalline substances act as three-dimensional diffraction gratings for X-ray 
wavelengths similar to the spacing of planes in a crystal lattice. X-ray diffraction is 
now a common technique for the study of crystal structures and atomic spacing.X-ray 
diffraction is based on constructive interference of monochromatic X-rays and a 
crystalline sample. These X-rays are generated by a cathode ray tube, filtered to 
produce monochromatic radiation, collimated to concentrate, and directed toward the 
sample. The interaction of the incident rays with the sample produces constructive 
interference (and a diffracted ray) when conditions satisfy Bragg's Law (nλ=2d sin θ). 
This law relates the wavelength of electromagnetic radiation to the diffraction angle 
and the lattice spacing in a crystalline sample. 
These diffracted X-rays are then detected, processed and counted. By scanning 
the sample through a range of 2θangles, all possible diffraction directions of the 
lattice should be attained due to the random orientation of the powdered material. 
Conversion of the diffraction peaks to d-spacing allows identification of the mineral 
because each mineral has a set of unique d-spacings. Typically, this is achieved by 
comparison of d-spacing with standard reference patterns.  
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All diffraction methods are based on the generation of X-rays in an X-ray 
tube. These X-rays are directed at the sample, and the diffracted rays are collected. A 
key component of all diffraction is the angle between the incident and diffracted rays. 
Powder and single crystal diffraction vary in instrumentation beyond this. 
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4. SCANNED ELECTRON MICROSCOPY: 
                                            
VEGA3 is a versatile system intended for both low and high vacuum 
operations providing users with the advantages of the latest technology, such as new 
improved high-performance electronics for faster image acquisition, an ultra-fast 
scanning system with compensation for static and dynamic image aberrations or 
scripting for user-defined applications. In addition, by means of powerful turbo-
molecular and rotary vacuum pumps, optimum operating vacuum is reached within 
few minutes. VEGA3 microscopes can be configured in 4 different chamber sizes: 
SB, LM, XM, and GM. These chambers are fitted with a variety of ports and designed 
with optimal geometry for EDX, WDX and EBSD analysis. VEGA3 is an excellent 
choice for those looking for a reliable and fully functional entry-level SEM system 
maintaining the best price-to-performance ratio. 
Equipment: specimen mounted on a 12.5mm stub with carbon tape and coated 
with conductive material (sputtered Au for example), stub tweezers. Using the Using 
the Electron Beam panel select an accelerating voltage (there are four factory presets 
(5kV, 10kV, 20kV, 30kV, image below). This will turn on the high voltage and begin 
heating the tungsten filament. 
 
 
 
 
 
 
  
 
 
 
 
TOXICOLOGICAL EVALUATION 
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4.5. TOXICOLOGICAL EVALUATION OF MANDURA CHENTHOORAM 
(MC): 
The following invivo toxicity studies were carried out on Mandura 
Chenthooram (MC) by using Organization for Economic Co-operation and 
Development (OECD) guidelines. 
1. Acute Oral Toxicity study (OECD guideline – 423)43 
2. Repeated Dose 28-days oral toxicity study (OECD guideline-407)44 
The toxicity studies were carried out at National Institute of Siddha. The study 
was done after getting permission from the Institutional Animal Ethical Committee. 
(IAEC Approved No: NIS/IAEC-II/09.2016) 
DESCRIPTION OF THE METHOD 
Selection of the animals:  
Animal were selected as per guidelines. The Wistar Albino Rats of weighing 
150-200g were obtained from authorized animal breeders of the animal laboratory in 
TANUVAS, Madhavaram, Chennai and stocked in the animal house at National 
Institute of Siddha, Chennai. Healthy adult animals of Wistar albino rat, female in sex 
used for acute oral toxicity study. Healthy adult animals of Wistar albino rat, both 
sexes were used for Repeated Dose 28-day oral toxicity study. The female animals 
used in the studies were nulliparous and non-pregnant. 
Housing and feeding conditions: 
The temberature in the experimental animal room: 22
0
C(±3
0
C). 
Humidity: 60 ± 10% 
Lighting: Artificial, the sequence being 12 hours light, 12 hours dark. 
The animals were housed in polypropylene cages provided with bedding of 
husk. 
The animals had free access to RO water. 
For feeding, standard pellet diet. 
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Preparation of animals: 
The animals were randomly selected, to permit individual identification by 
cage number and individual marking on the fur of each animal with picric acid. The 
animals were kept in their cages for 7 days prior to dosing to allow for acclimatization 
to the laboratory conditions. The principles of laboratory animal care were followed.  
Test Substance: 
Mandura Chenthooram, is dark red in colour, without taste and odour. 
Route of administration: 
Oral route was selected, because it is the normal route of clinical 
administration. 
Acute oral toxicity-experiment procedure: 
All the animals were fasted prior to dosing. Following the period of fasting, 
the animlas were weighed and then the test substance was administered. The control 
group received an equal amount of distilled water with honey. After the substance has 
been administered, food was withheld for a further 3-4 hours. The principle of 
laboratory animal care was followed. Observations were made and recorded 
systematically and continuously observed as per the guideline after substance 
administration. An oral dose of 300mg/kg.b.wt, 2000mg/kg.b.wt was administered 
step by step according to the guidelines (OECD Guideline). The general behaviours of 
the rat were continuously monitored for ½hr, 1hr, 2hr and 4hr after dosing, 
periodically during the first 24 hr with special attention given during the first 4 hours 
and then daily thereafter, for a total of 14 days. Changes in the normal psychomotor 
activity and external morphology and their body weights were monitored periodically 
before and the time at which signs of toxicity or mortality were recorded.  
Test animals: 
Species and strain   : Wistar Albino rat 
Sex     : Female 
Age, Weight    : 8-12 weeks, 150-200gm 
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Test guideline    : OECD guideline-423 
Groups/treatment   : Grouped by randomization 
During of exposure 
to the “Mandura Chenthooram” : single dose-one day 
Study duration   : 14 days –observation 
Number of animals   : 3 females/group 
Route of administration  : Oral  
Number of animals and dose levels: 
Animals were divided into 3groups, each group containing 3 female rats. One 
group as control and the other 2 groups II and III were treated with test drug 
Mandura Chenthooram at two different doses 300mg/kg.b.wt, 2000mg/kg.b.wt 
respectively. 
Grouping of animals in Acute Oral Toxicity study: 
Groups No of Rat 
Control:Vechicle control(Distilled Water with Honey) 3 female 
Group II: Test drug Mandura Chenthooram(300mg/kg.b.wt) 3 female 
Group III: Test drug ManduraChenthooram(2000mg/kg.b.wt) 3 female 
 
Observations: 
 Moratlity, behavioural changes, 
 ½hr, 1hr, 2hr, 4hr and upto 24 hour observation, 
 All rats will be observed twice daily on week days for 2 weeks, 
 Body weight will be monitored weekly once, 
 Feed and water intake will be calculated per day,  
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Cage-side observation: 
 
Clinical observation includes abnormal Gait (rolling and tiptoe), 
aggressiveness, akinesia, analgesia, catalepsy, convulsions, defecation, excitation, 
exopthalmos, head twitches, lacrimation, lethality, loss of corneal reflex, loss of 
righting reflex, loss of traction, piloerection, ptosis, reactivity to touch, respiration, 
salivation, scratching, sedation, stereotypies (chewing), stereotypies (head 
movements), stereotypies (sniffing), straub, tremor and writhes. 
 
Gross necropsy: 
At the end of the 14
th
 day  observation, all the animals were sacrificed by 
using Thiopentone Sodium gross necropsy includes examinations of the external 
surface of the body, all orifices, cranial, thoracic and abdominal cavities and their 
contents Brain, eye, heart, lungs, stomach,spleen, liver, kidneys, adrenals, uterus. 
 
REPEATED DOSE 28 DAYS ORAL TOXICITY STUDY 
Test animals: 
Species and strain   : Wistar Albino rats 
Sex     : Male and Female 
Age, Weight    : 6-8 weeks, 180-220gm 
Test guideline    : OECD guideline-407 
Groups/treatment   : Grouped by randomization 
Study duration   : 28 days  
Number of grouping   : 4 groups 
Number of animals   : 3males, 3females/group 
Route of administration  : Oral  
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Justification of dose selection: 
As stated results of acute toxicity studies in wistar albino rat indicated that 
Mandura Chenthoooram was not toxic up to the dose of 2000mg/kg.b.wt LD50. The 
oral route was selected for use because oral route is considered to be a proposed 
therapeutic route. The low dose was calculated from the therapeutic dose (130mg) and 
body surface area of the rat (0.018). Calculation of low dose – 130 X 0.018 = 
2.34/200gm of animal. 
Grouping of animals: 
Repeated dose 28 days oral toxicity study was carried out at different dose 
levels. The animals in both sexes were divided in four groups (Group I, II, III & IV). 
Each group consist of 3 animals (3 males and 3 females). Group – I served as control 
and the other three groups (II, III & IV) were treated as test group Low dose – 
2.34mg/kg.b.wt), Mid dose – 11.7mg/kg.b.wt), High dose – 23.4mg/kg.b.wt), 
respectively  
Grouping of animals in Repeated dose 28 days oral Toxicity study 
Groups No of Rats 
GroupI: Vehicle control(Distilled water with honey) 6 (3male, 3female) 
GroupII:Test drug(MC*)Low dose(2.34mg/kg.b.wt) 6 (3male, 3female) 
GroupIII:Test drug(MC*)Mid dose11.7mg/kg.b.wt) 6 (3male, 3female) 
Grou IV: Test drug(MC*)High dose 23.4mg/kg.b.wt) 6 (3male, 3female) 
*MC- Mandura Chenthooram 
Administration of doses: 
The animals were dosed with the drug daily for a period of 28 days. The test 
drug administered by oral gavage, and this was done in a single dose to the animals 
once in daily for 28 days. 
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Observations: 
 Moratlity, behavioural changes, 
 All rats will be observed twice daily on week days for 28 days, 
 Body weight will be monitored weekly once, 
 Feed and water intake will be calculated per day,  
Cage-side observation 
 
Clinical observation includes abnormal Gait (rolling and tiptoe), 
aggressiveness, akinesia, analgesia, catalepsy, convulsions, defecation, excitation, 
exopthalmos, head twitches, lacrimation, lethality, loss of corneal reflex, loss of 
righting reflex, loss of traction, piloerection, ptosis, reactivity to touch, respiration, 
salivation, scratching, sedation, stereotypies (chewing), stereotypies (head 
movements), stereotypies (sniffing), straub, tremor and writhes. 
 
Blood collection and laboratory investigations: 
At the end of 28 days, blood samples were collected just prior to euthanasia in 
all overnight (12 hours) fasted rats from abdominal aorta using sodium heparin 
containing vaccutainer (200IU/ml) for Blood chemistry and potassium EDTA 
containing vaccutainer (1.5mg/ml) for Haematology sample.  
 Complete Blood Count 
 Renal function test 
 Liver function test 
 Lipid profile 
Necropsy: 
By the end of 28 days, after blood collection, the animals were sacrificed by 
excessive anaesthesia. Animals were subjected to gross necropsy. Organs like heart, 
lung, kidney, liver, spleen, stomach, brain and sex organs were collected from all 
animals and preserved in 10% buffered neutral formation. 
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Histopathology: 
Control and highest dose groups animals will be initially subjected to 
histopathological investigation. If any abnormality found in the highest dose group 
then the low and mid dose group will also be examined. Various organs (brain, heart, 
lungs, liver, kidney, spleen, stomach, bone)will be collected from all the animals and 
preserved in 10% buffered neutral formalin, sliced , 5 or 6μm sections and will be 
stained with Hematoxylin and Eosin. Examined for histopathological changes. 
 
Statistical Analysis: 
Findings such as clinical signs of intoxication, body weight changes, food 
consumption, hematology, and biochemical parameters were subjected to one-way 
ANOVA followed by Dunnet “t” test using a computer software programme Graph 
Pad Instat-3. 
 
                                 RESULTS 
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5.1. QUALITATIVE ANALYSIS 
Table 1: Colour, nature of –Mandura Chenthooram: 
S.No Parameters Results Method of Testing 
1 Colour Dark red By visual 
2 Odour Odourless Olfactory examination 
3 Solubility i) Soluble in distilled 
water & honey 
ii) Sparingly soluble in 
distilled water 
Qualitative 
  
4 Nature Powder By visual 
From Table 1: The organoleptic characters show that Mandura Chenthooram is dark 
in colour and odourless powder form of drug. It is easily soluble in distilled water 
with honey and sparingly soluble in distilled water. 
Table 2: Physicochemical analysis of - Mandura Chenthooram: 
S.No Parameters Percentage 
1 Loss on drying Less than 1% 
2 Total ash value 99.67% 
3 Acid insoluble ash 94.99% 
4 Water soluble ash Less than 1% 
5 Water soluble extraction 0.68% 
6 Alcohol soluble extraction   2.1% 
7 pH Value 8.02 
From Table 2 : The Physico- chemical analysis of Mandura Chenthooram explained 
in the parameters such as Moisture content, Total ash value, Acid insoluble ash, Water 
soluble ash, Water soluble extraction, Alcohol soluble extraction  are within the 
normal limit. pH of the drug was  8.02, denotes it is alkaline. 
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Table 3: Biochemical analysis of Mandura Chenthooram (MC): 
S.No PROCEDURES RESULTS 
1 Test for Ammonium - 
2 Test for Sodium - 
3 Test for Magnesium - 
4 Test for Aluminium - 
5 Test for Pottasium - 
6 Test for Calcium + 
7 Test for Ferrous Iron + 
8 Test for Zing - 
9 Test for Arsenic - 
10 Test for Mercury - 
11 Test for Lead - 
12 Test for Sulphate + 
13 Test for Chloride - 
14 Test for Phosphate - 
15 Test for Carbonate + 
16 Test for Fluoride & Oxalate - 
17 Test for Starch + 
18 Test for Reducing sugar - 
19 Test for Alkaloids + 
20 Test for Amino Acids + 
21 Test for Unsaturated compounds - 
22 Test for type of compound 
 
+ 
(+)- Present; (-) – Absent 
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5.2. SPECTROSCOPIC ANALYSIS: 
1. ATOMIC ABSORPTION SPECTROSCOPY:  
Heavy metals content of Mandura Chenthooram was analyzed by AAS this 
results Tabulated in Table 4. 
Table-4: Analysis of Heavy Metals:  
S.No Name of the element Results 
1 Iron ( Fe) 22.60%. 
 
From Table 4: The Atomic Absorption Spectroscopy result shows that the heavy 
metal iron present in Mandura Chenthooram were found to be, at the same time the 
Iron content of test drug is 22.60%.  
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2. INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION 
SPECTROMETRY (ICP-OES): 
Weight of test drug: 0.51740g 
Table 5: Results of Quantitative analysis by ICP-OES for Mandura 
Chenthooram: 
S.No Elements Wave Length In 
(nm) 
Results(In Mg/L) 
1 Aluminium Al 396.152                  BDL 
 
2 Arsenic As 188.979 BDL 
3 Calcium Ca 315.807 03.550mg/L 
4 Cadmium Cd 228.802 BDL 
5 Copper Cu 327.393 BDL 
6 Iron Fe 238.204 201.770 mg/L 
7 Mercury Hg 253.652 BDL 
8 Potassium K 766.491 03.071 mg/L 
9 Magnesium Mg 285.213 01.104 mg/L 
10 Sodium Na 589.592 01.110 mg/L 
11 Nickel Ni 231.604 BDL 
12 Lead Pb 220.353 BDL 
13 Phosphorus P 213. 617 96.307 mg/L 
14 Sulphur S 180.731 01.224 mg/L 
 
BDL – Below Detection Limit 
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3. X-RAY DIFFRACTION PATTERN OF MANDURA CHENTHOORAM:   
Figure 1: EDAX analysis of Medicine sample: 
Table 6: Representing the weight and atomic percentage of elements present in 
Medicine sample: 
Element Weight% Atomic% Net Int. 
OK 41.54 62.18 504.89 
NaK 6.53 6.80 82.66 
AlK 3.79 3.37 145.58 
SiK 13.02 11.10 688.95 
KK 1.52 0.93 119.07 
CaK 7.22 4.31 519.53 
FeK 26.38 11.31 1210.18 
 
EDAX analysis shows the elements present in the sample as shown in Figure. 
The table represents the weight and atomic percentage of sample. The presence of 
iron is 26 Wt% and Oxygen is of 41.5 % during sample preparation sintering takes 
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place many time in presence of organic compounds of the iron gets more oxidized and 
the level of oxygen is increased. The presence of Si and Ca is small contributed by the 
presence of sand during sample collection and the Na and K are from the White Goat 
milk and Urine. Since the sample is subjected to the calcination processit became 
oxidized.  
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4. SCANNED ELECTRON MICROSCOPY: 
Determination of Particle size of Mandura Chenthooram 
Figure-2:  SEM Image of Mandura Chenthooram: 
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Description: 
The VEGA TESCAN 3 instrument is used with tungsten filament to image the 
samples. The SEM imaging of the Medicine prepared from iron oxide sample shows 
that the particles are in micro size and irregular in shape as shown in Figure 2. The 
particles are aggregate and individual particles are seen on the top of the clusters. 
Since the particles are collected from the raw iron oxide (Rust) the particle size is 
large. 
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5.3. TOXICICOLOGICAL EVALUATION: 
TOXICOLOGICAL EVALUATION OF MANDURA CHENTHOORAM (MC): 
A. ACUTE TOXICITY STUDY: 
Acute Toxicity Study was done as per OECD Guideline-423 with dose levels 
of 300, 2000 mg/kg.b.wt. Throughout the 14 days of observation period. 
Table 7: Dose finding experiment and behavioural Signs of Acute Toxicity Study 
on rat: 
No Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 300 + - - + + + - - - - - - - - - - - - + - 
2 2000 + - - + + + - - - - - - - - - - - - + - 
 
1.Alertness, 2.Aggressiveness, 3.Pile erection, 4.Grooming, 5.Gripping, 6.Tough 
response, 7.Decreased Motor Activity, 8.Tremors, 9.Convulsions, 10.Muscle Spasm, 
11.Catatonia, 12.Muscle relaxant, 13.Hypnosis, 14.Analgesis, 15. Lacrimation, 16. 
Exophthalmos, 17.Diarrhoea, 18.Writing, 19.Dyspnoea, 20. Mortality. 
+ Presence of Activity 
- Absence of Activity 
All the data were summarized in the form of (table-7) revealed that there was 
no abnormal signs and behavioural changes in all animals at the dose level of  
300,2000 mg/kg body weight administered orally, during the study period.   
There was no mortality observed after dosing of Mandura Chenthooram upto 
2000mg/kg body weight during the study period of 14 days. This indicates that the 
LD50 of Mandura Chenthooram is more than 2000mg/kg b.wt.  
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There were no changes in skin and fur, eyes and mucous membranes of all 
animals.  The eating, drinking habit, sleep pattern, locomotion were normal in all 
animals and no changes in body weight as compared to control group.  
At the end of the 14
th
 day, necropsy was performed and there was no 
abnormality seen in test groups as compared to control group during the examination. 
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B. REPEATED DOSE 28 DAYS ORAL TOXICITY STUDY:  
1. TABLES AND GRAPHS:  
Table 8: Food (g/day) intake of Wistar albino rats exposed to Mandura 
Chenthooram (MC): 
Dose(mg/day)/Day 1
st
 day 7
th
 day 14
th
 day 21
st
  day 28
th
 day 
CONTROL 54±12.72 42.5±3.53 51.5±2.12 56.5±2.12 67.5±6.36 
LOW DOSE 35±7.07 41.5±12.02 51±12.72 51±14.14 55.5±16.26 
MID DOSE 35.5±6.36 42.5±3.53 43±2.82 46.5±6.36 48.5±6.36 
HIGH DOSE 39±1.41 47.5±3.53 47.5±10.60 55±7.07 57±10.60 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 8: Food consumption of the animals no significant difference in food 
intake the test group animals were observed when compared with control group 
during the study period. 
Figure 3: Food (g/day) intake of Wistar albino rats exposed to Mandura 
Chenthooram (MC): 
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Table 9: Water (ml/day) intake of Wistar albino rats exposed to Mandura 
Chenthooram (MC): 
Dose(mg/kg) 1
st
day 
(ml/day) 
7
th
day 
(ml/day) 
14
th
day 
(ml/day) 
21
st
day 
(ml/day) 
28
th
day 
(ml/day) 
CONTROL 75±21.21 80±14.14 85±21.21 70±14.41 80±0 
LOW DOSE 80±0 105±7.07 95±21.21 80±14.14 80±0 
MID DOSE 80±14.14 80±28.28 75±7.07 80±0 85±7.07 
HIGH 
DOSE 
80±28.28 70±28.28 70±14.14 85±35.35 85±7.07 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 9: Water consumption the no difference in water intake of control and test 
group of animals observed during the study period (Table-9). 
Figure 4: Water (ml/day) intake of Wistar albino rats exposed to Mandura 
Chenthooram (MC): 
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Table10: Body weight (g) changes of Wistar albino rats (male) exposed to 
Mandura Chenthooram (MC): 
Dose  1
st
 day 
(mg/kg) 
7
th
 day 
(mg/kg) 
14
th
 day 
(mg/kg) 
21
st
 day 
(mg/kg) 
28
th
 day 
(mg/kg) 
CONTROL 154±5.24 206.66±14.57 216.66±18.17 231.66±29.29 245±39.88 
LOW DOSE 170.66±4.04 211.66±15.27 229.33±5.85 248.66±10.50 266.66±15.24 
MID DOSE 169±6.55 235±9.16 248±12.49 261±12.28 273±11.78 
HIGH 
DOSE 
197.33±32.88 221.66±36.50 240.33±35.92 252.33±37.07 261.33±35.92 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
 
Figure 5: Body weight (g) changes of Wistar albino rats (male) exposed to 
Mandura Chenthooram (MC): 
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Table 11: Body weight (g) changes of Wistar albino rats (female) exposed to 
Mandura Chenthooram (MC): 
Dose (mg/kg) 1
st
 day 7
th
 day 14
th
 day 21
st
 day 28
th
 day 
CONTROL 143.66±2.88 150±2.51 157±2.51 168±1.73 172.66±2.08 
LOW DOSE 146±6 153±2.88 160±2.64 171±6 178.33±7.63 
MID DOSE 148±3.46 158±5.03 165±5.13 173.33±2.51 180.66±1.52 
HIGH DOSE 150±9.86 160±16.82 170±16.16 179±19.51 185.33±18.61 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 10, 11: Body weight of the both control and test group exhibited normal 
body weight throughout the study period. 
Figure 6: Body weight (g) changes of Wistar albino rats (female) exposed to 
Mandura Chenthooram (MC):          
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Table 12: Effect of Mandura Chenthooram on Hematological Parameters: 
Parameters Control Low Dose Mid Dose High Dose 
RBC (X 10
6
µl) 6.08±0.81 6.48±1.75 6.73±0.87 6.61±0.91 
WBC(X10
3
µl) 9.06±1.79 9±1.82 8.75±1.86 8.76±0.94 
PLT(X10
3
µl) 668.66±131.49 765±132.74 790.66±117.92 715.16±134.51 
HGB(g/dl) 13.1±2.24 12.08±1.51 12.45±1.04 13.11±1.19 
MCH(pg) 16.81±2.37 17.85±1.92 18.33±1.71 19±2.31 
MCV(fl) 60.36±6.12 60.41±5.87 60.98±2.72 57.18±5.19 
NEUTROPHILS 
(10
3
/mm
3 
) 
1.71±0.44 1.75±0.61 1.53±0.46 1.7±0.60 
EOSINOPHILS(%) 1.46±0.18 1.5±0.17 1.53±0.26 1.31±0.29 
BASOPHILS(%) 0.16±0.40 0.33±0.51 0.16±0.40 1.31±0.29 
LYMPH(%) 71.45±11.29 75.61±12.50 74.25±9.39 70.68±6.47 
MON(%) 2.51±0.67 2.7±0.76 2.68±0.58 1.86±1.04 
 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 12: The results of the Haematological investigations conducted at the end 
of the study, the test groups revealed no significant changes in levels of 
haematological parameters, when compared with control group. 
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Figure 7: Effect of Mandura Chenthooram on RBC: 
 
        
 
Figure 8: Effect of Mandura Chenthooram on WBC: 
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Figure 9: Effect of Mandura Chenthooram on PLT: 
         
Figure 10: Effect of Mandura Chenthooram on Haemoglobin    
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Figure 11: Effect of Mandura Chenthooram on MCH and MCV: 
 
Figure 12: Effect of Mandura Chenthooram on Leucocytes: 
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Table 13: Effect of Mandura chenthooram on Biochemical Parameters - Renal 
function test: 
Parameters Control Low Dose Mid Dose High Dose 
BUN (mg/dl) 14.91±4.93 18.18±3.48 16.9±2.30 17.45±3.14 
Serum 
Creatinine(mg/dl) 
0.78±0.19 0.76±0.13 0.73±0.24 0.76±0.18 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 13: The results of the Renal function test conducted at the end of the 
study, the test groups revealed no significant changes in levels of haematological 
parameters, when compared with control group. 
Figure 13: Effect of Mandura chenthooram on Biochemical Parameters - Renal 
function test: 
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Table 14: Effect of Mandura chenthooram on Biochemical Parameters - Liver 
function test: 
Parameters Control Low Dose Mid Dose High Dose 
Total 
Bilirubin(mg/dl) 
0.51±0.14 0.41±0.21 0.45±0.08 0.43±0.12 
SGOT(IU/ml) 121.33±16.08 120.5±27.14 117.83±21.60 107.16±34.38 
SGPT(IU/ml) 31±10.29 27.5±5.54 29.33±3.72 33.5±8.16 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 14: The results of the Liver function test conducted at the end of the 
study, the test groups revealed no significant changes in levels of haematological 
parameters, when compared with control group. 
Figure 14: Effect of Mandura chenthooram on Biochemical Parameters - Liver 
function test 
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Table 15: Effect of Mandura chenthooram on Biochemical Parameters - Lipid 
Profile 
Parameters Control Low Dose Mid Dose High Dose 
Total 
Cholesterol(mg/dl) 
145.63±23.28 121.75±19.91 136.76±13.79 139.96±8.64 
HDL(mg/dl) 65.83±12.36 64.83±11.54 64.83±13.94 59.33±11.70 
LDL(mg/dl) 64.66±20.06 39.33±15.78 56.66±12.51 64.33±17.96 
VLDL(mg/dl) 15.13±1.81 17.58±3.57 15.26±4.60 16.3±3.12 
TGL(mg/dl) 43.33±12.50 41.83±10.00 34.66±8.61 39.16±4.99 
Values were expressed as mean± S.D. for N=6 rats in each group one-way ANOVA 
followed by Dunnett’s test. Significant indicates that *P<0.05, **P<0.01 
From Table 15: Biochemical investigations were conducted at the end of the study 
and the results were recorded. In test groups there was no significant change present 
in biochemical parameters, when compared with the control group. At the values were 
normal biological limits. 
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Figure 15: Effect of Mandura chenthooram on Biochemical Parameters - Lipid 
Profile: 
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Histopathology of Brain 
                                        High Power Magnification 40X   
              PLATE: A CONTROL (M)                       PLATE: A CONTROL (M)           
                                   
               PLATE: C HIGH DOSE (M)                    PLATE: D HIGH DOSE (FM) 
                      
  PLATE: A -The cerebral sections showed normal architecture in both cortex    
and  medulla. 
            PLATE: B -Appearance of Hippocampal neurons was normal with dense 
network.  
                                -Morphology of neurons in CA1, CA2 and CA3 zones are normal. 
 PLATE: C -Arrangement of neurons on cerebral cortex appears normal and 
dense. 
                                -No signs of ischemia or lesion were observed. 
PLATE: D -Normal architecture was observed in both cortex and medulla of     
cerebellum. 
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Histopathology of Heart 
High Power Magnification 40X 
         PLAET: A CONTROL (M)                        PLATE: B CONTROL (FM) 
                                      
       PLATE: C HIGH DOSE (M)                  PLATE: D HIGH DOSE (FM) 
                            
              
    PLATE: A-Appearance of myocyte was normal. 
    PLATE: B -Appearance of fibrils and cross striations are normal and equidistant. 
    PLATE: C- Nucleus appears prominent with regular arrangement of fibres.  
                        -No evidence of   pyknotic nucleus. 
    PLATE: D- Myocardial cells appears normal with well-defined mycoplasma and   
prominent nucleus and nucleolus. 
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Histopathology of Lung  
High Power Magnification 40X 
                      PLATE: A CONTROL (M)                     PLATE: B CONTROL (FM) 
                                           
                    PLATE: C HIGH DOSE (M) PLATE: D HIGH DOSE (FM) 
                                         
  
 PLATE: A- Lung parenchyma appears normal with regular arrangement 
of alveoli and alveolar sac. 
 PLATE: B-Perivascular region appears normal, alveolar septa and wall 
appeared widen and normal. 
 PLATE: C- Bronchial opening appears regular with no signs of 
infiltration. 
                    PLATE: D- Appearance of alveolar network was normal. 
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Histopathology of Stomach  
High Power Magnification 40X 
     PLATE: A CONTROL (M)                          PLATE: B CONTROL (FM) 
                                     
             PLATE: A CONTROL (M)                          PLATE: B CONTROL (FM) 
                                 
 
 PLATE: A- The continuity of mucosa was normal with no evidence of 
ulceration. 
           PLATE: B- Appearance of Sub-mucosa and gastric glands appear normal. 
           PLATE: C- Mucosal wall appears normal with regular arrangement of  
connective Tissue. 
           PLATE: D- Gastric glands including secretary sheath appears normal. 
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Histopathology of Liver 
High Power Magnification 40X 
  PLATE: A CONTROL (M)                         PLATE: B CONTROL (FM) 
                                   
PLATE: C HIGH DOSE (M)                       PLATE: D HIGH DOSE (FM) 
                        
 
PLATE: A - Section of liver showing normal hexagonal hepatic lobules with 
normal, regular radiated hepatic cords. 
PLATE: B - Hepatocytes appear variably pale with mild congestion on central 
vein. 
PLATE: C - Centrilobular zone appears normal with stable network of 
hepatocytes. 
PLATE: D - Appearance of terminal hepatic venules (central veins) to the 
portal tracts was normal. 
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       Histopathology of Spleen 
                                     High Power Magnification 40X 
    PLATE: A CONTROL (M)                       PLATE: B CONTROL (FM) 
                              
PLATE: C HIGH DOSE (M)                       PLATE: D HIGH DOSE (FM) 
                              
            
  PLATE: A – Marginal sinus (MS) of the spleen and its sinus lining cells 
appears normal. 
PLATE: B – Erythropoietic cells (EP) are scattered throughout the red pulp. 
No abnormalities found in lymph node.  
PLATE: C – Presence of marginal at the interface of the red pulp with the 
PALS and follicles was observed. 
PLATE: D - Marginal sinus of the spleen and its sinus lining cells appears 
normal. 
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        Histopathology of Kidney 
                                     High Power Magnification 40X 
    PLATE: A CONTROL (M)                         PLATE: B CONTROL (FM) 
                          
PLATE: C HIGH DOSE (M)                       PLATE: D HIGH DOSE (FM) 
                        
 
PLATE: A – Section showing normal, intact renal tubules as well as renal 
glomeruli. 
PLATE: B – Arrangement of glomerular loop was normal with regular 
interstitium. 
            PLATE: C – Some renal tubules are hypertrophic, others are dilated. 
PLATE: D - Appearance of proximal and distal convolutes tubules was 
normal with no evidence of atrophy. 
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    Histopathology of Testes 
                                     High Power Magnification 40X 
       PLATE: A CONTROL (M)                          
                                                          
PLATE: B HIGH DOSE (M)                              
                                                          
                 
PLATE: A – Section of testis of showing normal interstitial connective tissue with 
proliferating highly divided germ cells with elongated sertoli cells. 
PLATE: B – Testicular tissue shows well differentiated germ cells with respect of 
spermatogonia include spermatid and sperm were observed.             
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Histopathology of Ovary 
                                           High Power Magnification 40X 
          PLATE: A CONTROL (FM) 
                                              
                                              PLATE: B HIGH DOSE (FM) 
                                             
                
PLATE: A – Sequential arrangement of granulosa cells around oocyte was normal 
and regular.             
PLATE: B – Appearance of antral follicle, primary oocyte and secondary follicles are 
normal. 
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      Histopathology of Uterus 
                                               High Power Magnification 40X 
            PLATE: A CONTROL (FM) 
                                              
                                               PLATE: B HIGH DOSE (FM) 
                                             
                
PLATE: A – Appearance of endometrium, myometrium and uterine glands was 
normal. 
PLATE: B – Endometrial gland, epithelium and blood vessels appears normal. 
 
 
 
                     Discussion 
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DISCUSSION 
After the preparation of the test drug Mandura Chenthooram it undergone 
Physico-chemical, Biochemical, AAS, ICP-OES, XRD, SEM, Analysis and Toxicity 
study and their results are discussed as follows.   
  The Physico - chemical analysis of MC (Table: 2) concludes the following results       
    The loss on drying test is designed to measure the amount of water and volatile 
matters in a sample when the sample is dried under specified conditions. The 
percentage of loss on drying of MC was less than 1%.   
           The Ash limit Tests are designed to measure the amount of the residual. A high 
ash value is indicative of contamination, substitution, adulteration or carelessness in 
preparing the drug. The total ash values of MC were 99.67%. Acid-insoluble ash 
value of MC is 94.99%. Extraction value determines the amount of active constituents 
in a given amount of the formulation when extracted with a solvent media such as 
water and alcohol. pH of the drug was 8.02, denotes it is alkaline.  
   Qualitative Analysis of Mandura Chenthooram (Table-3) indicates the 
presence of Silicate, Sulphate, Carbonate, Iron, Calcium, Alkaloid, Starch and 
presence of Anti pyrine, Aliphatic amino acid, Meconic acid.  
   The Atomic Absorption Spectroscopy result (Table-4) shows that the heavy 
metal iron present in Mandura Chenthooram were found, at the same time the Iron 
content of test drug is 22.60%.  
The Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) 
results showed that the Heavy metals like Aluminium, Arsenic, Cadmium, Copper, 
Mercury, Nickel and Lead were found below detection level. It also shows the 
presence of physiologically important minerals like Calcium, Copper, Sodium, 
Magnesium, Potassium, Sulphur and Phosphorus. (Table-5)   
 EDAX analysis shows the elements present in the sample as shown in Figure- 
1. The table (Table-6) represents the weight and atomic percentage of sample. The 
presence of iron is 26 Wt% and Oxygen is of 41.5 % during sample preparation 
sintering takes place many time in presence of organic compounds of the iron gets 
more oxidized and the level of oxygen is increased. The presence of Si and Ca is 
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small contributed by the presence of sand during sample collection and the Na and K 
are from the White Goat milk and Urine. Since the sample is subjected to the 
calcination process, it became oxidized.  
The SEM imaging of the Medicine prepared from iron oxide sample shows 
that the particles are in micro size and irregular in shape as shown in Figure-2. The 
particles are aggregate and individual particles are seen on the top of the clusters. 
Since the particles are collected from the raw iron oxide (Rust) the particle size is 
large. 
In Acute Toxicity Study, carried out as per OECD guidelines 423, there were 
no treatment related death or signs of toxicity developed in wistar albino rat at dosage 
levels of  300 and 2000 mg/kg b.wt throughout the study period. Further, no gross 
pathological changes have been seen in the internal organs of both control and treated 
groups. Thus, the LD50 value was found to be greater than 2000mg/kg body weight. 
28 Days Repeated Oral Toxicity Study was conducted as per the OECD 
guidelines - 407 in 4 doses. Control group was administered 1ml of honey mixed with 
1ml of distilled water. The low dose was calculated from the approximate therapeutic 
dose (130 mg) and body surface area of rat (0.018). Calculation of low dose – 130 × 
0.018 = 2.34 mg/200 gm of animal. Mid dose was calculated as (2.34 x 5=11.7mg) 
and high dose was calculated as (2.34 x 10=23.4mg). Animals were observed 
throughout the period. There was no significant change in food intake (Table-8), 
water intake (Table-9), and body weight (Table-10, 11). After 28 days animals were 
sacrificed and blood samples were collected, investigated. The results revealed that 
there were no significant changes in the haematological parameters (Table-12), 
biochemical parameters (Table 13,14,15 ) , The histopathological study on the organs 
such as brain, heart, lungs, stomach, liver, spleen, kidney, testes, ovary and uterus was 
normal in control, and high dose groups. 
 
                        Summary 
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SUMMARY 
The branch of toxicology (Nanju Murivu Maruthuvam) was developed in 
Siddhar’s period itself. Being a toxicology student the author is interested to take the 
drug Mandura Chenthooram to evaluate its safety profile. The name, Mandura 
Chenthooram comes from its ingredients manduram useful to treat various blood 
disorders.  
               Mandura Chenthooram is a Siddha formulation prepared from purified 
Manduram (Ferroso ferric oxide), Pasuneer (Cow urine), Vetrilai (Piper betel), 
Vellattupaal (Goat milk), Vellattu neer (Goat urine), Notchi (Vitex negundo), and 
Katrazhai (Aloe vera).           
The test drug was chosen from the Siddha literature Kannusamy Parambarai 
Vaithiyam. The raw drugs were procured from Ramasamy Chetti shop and 
authenticated at Department of Gunapadam, National Institute of Siddha, Chennai-47. 
The Herbal drugs were identified and authenticated by Assistant Professor, 
Department of Medicinal Botany, National Institute of Siddha, Chennai-47. The 
ingredients were purified and the medicine was prepared as mentioned in the Siddha 
literature.           
Mandura Chenthooram was analyzed qualitatively with physico chemical, 
biochemical analysis, and spectroscopically with AAS, ICP-OES, XRD, SEM 
analysis. Acute and repeated dose 28 days oral toxicity studies were conducted as per 
the OECD guidelines  
   Initially the test drug was subjected to physico chemical analysis. It reveals the 
increased bioavailability and purity of the drug. Then the samples were analysed for 
Biochemical constituents. It reveals the presence of constituents like Silicate, 
Sulphate, Carbonate, Iron, Calcium, Alkaloid, Starch, Anti pyrine, Aliphatic amino 
acid and Meconic acid.  
The Atomic Absorption Spectroscopy result shows the presence of heavy 
metal iron in Mandura Chenthooram and the Iron content of test drug is 22.60%.  
The Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) 
shows that Aluminium, Arsenic, Cadmium, Copper, Mercury, Nickel and Lead were 
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found below detection level. It also shows the presence of physiologically important 
minerals like Calcium, Copper, Sodium, Magnesium, Potassium, Sulphur and 
Phosphorus.  
 EDAX analysis shows the presence of elements in the sample Iron, Oxygen, 
Sodium, Aluminium, Silicate, Potassium, and Calcium.  
The SEM imaging of the Medicine prepared from iron oxide sample shows 
that the particles are in micro size and irregular in shape. The particles are aggregate 
and individual particles are seen on the top of the clusters since the size of the 
particles collected from the raw iron oxide (Rust) is large. 
In Acute Toxicity Study, carried out as per OECD guidelines 423, there were 
no treatment related death or signs of toxicity developed in wistar albino rat at dosage 
levels of  300 and 2000 mg/kg b.wt throughout the study period. Further, no gross 
pathological changes have been seen in the internal organs of both control and treated 
groups. Thus, the LD50 value was found to be greater than 2000mg/kg body weight. 
Repeated Oral 28 Days Toxicity Study was conducted for about 28 days as per 
the OECD guideline-407 in 4 doses. Control group were given 1ml of honey with 1 
ml distilled water. Low dose, mid dose and high dose were 2.34mg, 11.7mg and 
23.4mg respectively. There was no significant change in body weight, water and food 
intake. There were no significant changes in the haematological and biochemical 
parameters. Histopathological study shows that, organs such as brain, heart, lungs, 
stomach, liver, spleen, kidney, testes, ovary and uterus was normal in control, and 
high dose groups. 
 
                     Conclusion 
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CONCLUSION 
Mandura Chenthooram had been used by Siddhars for long time to treat 
various diseases such as Anaemia, Dropsy, Jaundice, Ascites, Cough, and Diarrhoea.   
Since Iron Oxide is present in Mandura Chenthooram, which is observed by the 
quantitative analysis, the drug can be easily absorbed in intestine. Acute toxicity  
study shows  that  the  test  drug  can  be  used  up  to  the  dose  of 2000mg/kg body 
weight as a single dose.  As per Siddha literature, the test drug was used as a minimal 
dose medicine. No notable abnormalities were observed in test group of animals when 
compared with control group of animals. Hence, we conclude  that  the  dosage  of  
Mandura Chenthooram,  130mg  twice a  day  narrated  in  Kannusamy Parambarai 
Vaithiyam is a safer therapeutic dose for  uses of human. The author hopes that this 
study will be a footprint to future research of chronic toxicity study, Carcinogenicity, 
Teratogenicity regarding Mandura Chenthooram. 
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